methods for producing antibody or light or heavy chain of antibody specific to a desired antigen, fo

专利摘要:
METHOD FOR THE PRODUCTION OF SPECIFIC ANTIBODY OR LIGHT OR HEAVY ANTIBODY CHAIN FOR A DESIRED ANTIGEN, FOR THE PRODUCTION OF TOTALLY HUMANIZED ANTIBODY OR ANTIBODY CHAIN OR ANTIBODY CHAIN AND ITS USE, PHARMACEUTICAL AND PHARMACEUTICAL PHARMACEUTICAL COMPOSITION.The present invention relates to methods for generating antibodies human chimeric and non-human chimeric chains of antibodies, antibodies and chains of antibodies thus produced, and derivatives thereof, including fully humanized antibodies, compositions comprising said antibodies, chains and derivatives of antibodies as well as cells, non-human mammals and vectors, suitable for use in said methods.
公开号:BR112012000536A2
申请号:R112012000536-7
申请日:2010-07-07
公开日:2020-08-11
发明作者:Allan Bradley；E-Chiang Lee；Qi Liang；Wei Wang
申请人:Kymab Limited；
IPC主号:

专利说明:

Invention Patent Descriptive Report for "METHODS FOR THE PRODUCTION OF ANTIBODY OR LIGHT OR HEAVY CHAIN OF. ANTIBODY SPECIFIC TO A DESIRED ANTIGEN, FOR THE PRODUCTION OF THE ANTIBODY OR TOTALLY HUMAN — ANTIBODY OR ANTIBODY CHAIN AND ANTIBODY OR ANTIBODY OR ANTIBODY OR ANTIBODY OR ANTIBODY OR ANTIBODY OR ANTIBODY ITS USE, PHARMACEUTICAL COMPOSITION AND CHEMICAL ANTIBODY DERIVATIVE ", Background The present invention relates, inter alia, to animals and non-human cells that are constructed to contain exogenous DNA, such as the DNA of the human deimmunoglobulin gene, its use in medicine and in the study of diseases, methods for the production of non-human animals and cells and antibodies and chains of antibodies produced by these animals and their derivatives.
In order to circumvent the problems encountered when humanizing antibodies, some companies have started to generate mice with human immune systems.
The strategy used was to silence (knockouf) the expression of heavy and light chain / oci in ES cells (embryonic stem cells) and complement these genetic lesions with transgenes designed to express human heavy and light chain genes. .
Although fully human antibodies could be generated, these models suffer from several important limitations: (i) The size of the heavy and light chain loci (each of several Mb) prevented them from being introduced entirely into these models.
As a result, the repertoire of V regions of the recovered transgenic lines was very limited, most of the constant regions were missing and important distant intensifying regions were not included in the transgenes. (ii) The very low efficiency of generating the large transgenic strains inserted and the complexity and time required to cross each one of them in the silenced strains (Knockout) of heavy and light chain and to make them homozygous again they restricted the number of transgenic strains — which could be analyzed for ideal expression. (iii) The individual affinities of the antibodies rarely reached those that could be obtained from intact (non-transgenic) animals. WOZ2007117410 describes chimeric constructs
% for expression of chimeric antibodies.
WOZ2010039900 describes the knock in process (elimination or replacement of one or more bases) in cells and mammals with a genome encoding chimeric antibodies.
The present invention provides, inter alia, a process for the generation, in non-human mammals, of antibodies that comprise a human variable region of Ig and further provides models of non-human animals for the generation of such antibodies.
Summary of the invention In one aspect, the invention relates to a non-human mammal whose genome comprises: (a) a plurality of human IgH V regions, one or more human D regions and one or more human J regions in upward to the host non-human mammal constant region, e] 15 (b) optionally one or more human kappa lg light chain V regions and one or more human J regions of the lg kappa light chain upward to the region kappa constant of the non-human host mammal and / or one or more human V regions of the lg lambda light chain upwards to the lambda constant region of the host non-human mammal; in which the non-human mammal is capable of producing a repertoire of chimeric antibodies, or chimeric heavy and light chains, having a constant region of non-human mammal and a human variable region.
In one aspect, the invention relates to a non-human-nocturnal mammal comprising: (a) a plurality of human kappa light chain V regions of lg and one or more human J regions of kappa light chain of lg in an upward direction - tooth to the kappa constant region of the host non-human mammal and / or a plurality of human lambda light chain V regions of lg and one or more human regions of the lambda light chain of lg upwards to the lambda constant region of the host non-human mammal ; and (b) optionally one or more human IgH V regions, one or more |
7 human D regions and one or more human J regions upward to the constant region of the host non-human mammal; In which the non-human mammal is capable of producing a repertoire of chimeric antibodies, or chimeric light or heavy chains, having a non-human mammalian region and a variable human region. In one aspect, the invention relates to a non-human mammalian cell whose genome comprises: (a) a plurality of human V regions of IgH, one or more human J regions upward to the constant region of the non-human mammal host and (b) optionally one or more human Ig kappa light chain V regions and one or more human kappa light chain J regions from lg upwards to the kappa constant region of the host non-human mammal and one or more V regions human Ig light lambda chains and one or '15 more human Ig light lambda regions upward to the lambda constant region of the host non-human mammal.
In one aspect, the invention relates to a non-human mammalian cell whose genome comprises: (a) a plurality of human Ig kappa light chain V regions and one or more human regions of lg kappa light chain upwards the kappa constant region of the host non-human mammal and / or a plurality of human lambda Ig light chain V regions and one or more human lambda Ig light chain regions upward to the lambda constant region of the non-human mammal host; and (b) optionally one or more human V regions of IgH, one or more human D regions and one or more human J regions upwardly to the constant region of the host non-human mammal.
In another aspect, the invention relates to a method for producing a non-human cell or mammal comprising inserting a non-human mammalian cell into the genome, such as an ES cell genome: (a) a plurality of human V regions of IgH, one or more human D regions and one or more human J regions upward to the region |
- constant of the host non-human mammal; and (b) optionally one or more human Kappa light chain V regions of 'lg and one or more human Kappa light chain J regions of lg upwardly to the kappa constant region of the host non-human mammal and one or more human light chain V regions Ig lambda and one or more human lambda light chain J regions of lg upward to the lambda constant region of the host non-human mammal; respectively, the insertion being such that the cell or non-human mammal is capable of producing a chimeric antibody repertoire having a non-human mammal constant region and a human variable region, in which steps (a) and ( b) can be carried out in any order and each "of steps (a) and (b) can be carried out in steps or in a single step.
The insertion can be by homologous recombination.
In another aspect, the invention relates to a method for producing an antibody or antibody chain specific for a desired antigen, the method comprising immunizing a transgenic non-human mammal, as described in this patent application, with the antigen and recover the antibody or antibody chain.
In a further aspect, the invention relates to a method for producing a fully humanized antibody, comprising immunizing a transgenic non-human mammal, as described in this patent application, with the desired antigen, recovering the antibody or producing cells of the antibody and then replace the non-human mammal constant region with a human constant region, for example, by protein or DNA engineering.
In another aspect, the invention relates to humanized antibodies and chains of antibodies produced in accordance with the present invention, both in chimeric (for example, mouse-human) and fully humanized form, as well as fragments and derivatives of said antibodies and chains, and the use of said antibodies, chains and fragments in medicine, including in diagnosis.
|
: In another aspect, the invention relates to the use of a non-human mammal, as described in this patent application, as a model for drug and vaccine testing. Figures Figures 1 - 8 show an iterative process for introducing a series of human BACs in a mouse Ig locus. Figures 9 - 18 show in more detail the process in Figures 1 - 8 for IgH and kappa locus. Figures 19 and 20 show the principles underlying antibody generation in chimeric mice. Figure 21 shows a possible insertion site for DNA: human on a mouse chromosome. Figures 22 - 26 describe an alternative iterative process CU for insertion of human BACs into a mouse Ig locus. Figures 27 - 29 illustrate a mechanism for reversing the host region. Figure 30 illustrates the proof of principle for insertion of a plasmid with RMCE approach. Figure 31 illustrates the RMCE process - Integration sequenced in Landing Pad (landing platform). Figure 32 illustrates confirmation of successful insertion into the Landing Pad. Figure 33 illustrates the PCR confirmation of cure of the 3 'end. Figure 34 illustrates the insertion of BAC # 1 and diagnosis by P-
CR General description All nucleotide coordinates for the mouse come from NCBI m37, April 2007 ENSEMBL Release 55.37h for the C57BL / 6J strain of mice. Human nucleotides come from GRCh37, Feb2009ENSEMBL Release 55.37 and from RGSC rats 3.4 Dec 2004 EN-SEMBL release 55.34w. In the present invention, methods for construction are described |
. chimeric loci of human heavy and light chains in a non-human mammal, for example, a mouse.
In this descriptive report, reference, work on mice is provided for purposes of example only, and reference to mice should be understood as including reference to all non-human mammals unless otherwise evident from the 'descriptive report, with mice being preferred. like the non-human mammal.
In one aspect, the invention relates to a non-human mammal whose genome comprises: (a) a plurality of human V IgH regions, one or more human D and one or more human J regions upward to the constant region - from the host non-human mammal; and CS (b) optionally one or more human Kappa light chain V regions of. 1g and one or more human kappa light chain J regions of lg in an upward direction to the host kappa constant region of the non-human mammal and / or one or more human lambda Ig light chain V regions and one or more human J regions IgB lambda light chain upwards to the lambda constant region of the host non-human mammal; Wherein the non-human mammal is capable of producing a repertoire of chimeric antibodies or antibody chains having a non-human mammal constant region and a human variable region.
In another aspect, the invention relates to a non-human mammal whose genome comprises: (a) a plurality of human Ig kappa light chain V regions and one or more human regions of lg kappa light chain upwards to the kappa constant region of the host non-human mammal and / or a plurality of human lambda Ig light chain V regions and one or more human lambda Ig light chain regions upward to the lambda constant region of the non-human mammal host; and (b) optionally one or more human IgH V regions, one or more human D regions and one or more human J regions upwardly to the constant region of the host non-human mammal; |
7I58. wherein the non-human mammal is capable of producing a repertoire of chimeric antibodies having a constant region of the non-human mammal and a human variable region. Optionally, the non-human mammalian genome is modified | 5 doparaimpedira the expression of complete species-specific antibodies: the host.
In one respect, the inserted human DNA comprises at least 50% of the human heavy chain variable region (V) genes, such as at least 60%, at least 70%, at least 80%, at least 90% * and, in one respect, all human V genes. : In one respect, the inserted human DNA comprises at least 50% of the diversity region (D) genes of the human heavy chain, Fa as at least 60%, at least 70%, at least 80%, at least 90% and, in one respect, all human D genes. ] 15 In one respect, the inserted human DNA comprises at least 50% of the human heavy chain (J) junction region genes, such as at least 60%, at least 70%, at least 80%, at least 90% and, in one respect, all human J genes. In one aspect, the inserted human DNA comprises at least 50% of the human light chain Variable (V) region genes, such as at least 60%, at least 70%, at least 80%, at least 90% and, in one respect, all human V light chain genes.
In one respect, the inserted human DNA comprises at least 50% of the human light chain splicing region (J) genes, such as at least 60%, at least 70%, at least 80%, at least 90% and , in one aspect, all human light chain J genes.
The inserted human genes can be derived from the same or different individuals, or be synthetic or represent consensus human sequences.
Although the number of V, D and J regions is variable between human individuals, in one aspect, 51 human V genes, 27 D genes and 6 J genes in the heavy chain, and 40 human V genes and 5 are considered |
. J genes in the kappa light chain and 29 human V genes and 4 J genes in the lambda light chain (Janeway and Travers, Immunobiology, Third edition). 'In one aspect, the human heavy chain / ocus inserted in the non-human mammal contains the complete repertoire of human V, De J regions present in the genome in functional arrangement with the non-human mammal's constant regions so that antibodies Functional chimerics can be produced between human variable regions and those of non-human mammals. This total inserted human heavy chain genetic material is designated in this specification as the human VgD region of IlgH and comprises the DNA of a human genome that encodes all exons encoding human V, D and J portions, in addition to adequately associated introns. Likewise, reference to the human kappa light chain V and J regions, in this specification, refers to human DNA comprising all exons encoding V and y regions, in addition to suitably the associated introns of the human genome. Reference to the human lambda light chain V and J regions of lg, in this specification, refers to human DNA comprising all exons coding for regions V and J, in addition to suitably the introns associated with the human genome.
Human variable regions are suitably inserted upwards to the non-human mammal constant region, the latter comprising the complete constant region or a part of the constant region that allows the formation of an effective chimeric antibody, capable of specifically recognizing an antigen.
In one aspect, chimeric antibodies or chains of antibodies have part of a constant region of the host sufficient to enable one or more effector functions seen in natural antibodies in a host mammal, for example, to allow them to interact with Fc and / or to bind to the complement.
In this specification, therefore, reference to a chimeric antibody or antibody chain having a host non-human mammal constant region is not limited to the complete, but in- |
. it also includes antibodies or chimeric chains that contain the entire host constant region, or a part of it sufficient to enable one. or more effector functions. The same applies to mammals and non-human cells and to methods of the invention in which the DNA of a variable region | 5 can be inserted into the host genome in such a way that it forms: a chimeric antibody chain with all or part of a constant region of the host. In one respect, the entire host region is operationally linked to the DNA of a variable human region.
In this specification, the host non-human mammal constant region is preferably the host endogenous constant region, located in the wild type locus, as appropriate for the heavy or light chain. For example, DNA from the human heavy chain is suitably inserted into mouse chromosome 12, suitably adjacent to the constant region of the mouse heavy chain.
In one aspect, the insertion of human DNA, such as the region: Human VDJ is directed to the region between the J4 exon and the Cu locus at the IgH locus in the mouse genome and, in one aspect, it is inserted between the 114,667 coordinates .090 and 114,665,190, appropriately coordinated 114,667,091. In one aspect, the insertion of human DNA, such as human kappa light chain VJ is directed to chromosome 6 of mice, between the coordinates 70.673.899 and 70.675.515, suitably at position 70.674.734, or in an equivalent position on the mouse / lambda ocus on chromosome 16.
In one aspect, the constant region of the host non-human mammal to form the chimeric antibody may be at a different (non-endogenous) chromosomal locus. In this case, the inserted human DNA, such as the human VDJ or variable VJ region (s), can be inserted after a non-human genome at a site other than that of the constant heavy or light natural region . The native constant region can be inserted into the genome, or duplicated within the genome, at a different chromosomal locus |
: close to the native position, in such a way that it is in a functional arrangement with the human variable region and that chimeric antibodies of the invention can still be produced. In one aspect, human DNA is inserted into the host's endogenous wild-type constant region, located in the wild-type locus between the host's constant region and the host's VDJ region.
Reference to the location of the variable region upward to the constant region of the non-human mammal means that there is an adequate relative location of the two portions of the antibody, variable and constant, to allow the variable region and the constant to form an anti-: body chimeric or antibody chain in vivo in the mammal. As a result, the inserted human DNA and the constant region of the host are in a functional arrangement with each other for the production of antibodies or antibody chains.
] 15 In one aspect, the human DNA inserted is able to be expressed with different regions of the host by switching (isotypic change) of isotypes. In one respect, isotype switching does not: require or involve trans switching. The insertion of the DNA of the human variable region on the same chromosome as the relevant constant region of the host means that there is no need for trans switching to produce isotypic variation.
As explained above, the transgenic loci used for the prior art models were of human origin, so even in those cases where the transgenes were capable of complementing the mouse / locus so that the mice produced B cells producing fully human antibodies, the individual affinities of antibodies rarely reached those that could be obtained from intact (non-transgenic) animals. The main reason for this (in addition to the repertoire and levels of expression described above) is the fact that the locus control elements are human. Therefore, signaling components, for example, to activate hypermutation and the selection of high affinity antibodies are compromised.
|
. In contrast, in the present invention, the constant regions of the host non-human mammal are maintained, and it is preferred that at least one enhancer or other control sequence of the non-human mammal, as a switch region, is maintained in a functional arrangement i 5 the constant region of the non-human mammal, so that the effect of the enhancer or other control sequence as seen in the host mammal is exerted in whole or in part in the transgenic animal.
This approach above is created so that all the diversity of the human locus can be sampled, to allow the same high levels of expression that would be achieved by mammalian control sequences: non-human, such as enhancers, and it is such that signaling in the cell B, for example, switching isotypes using recombined sites for. ” isotypic variation, would still use sequences from the non-human mammal. A mammal with such a genome would produce chimeric antibodies with variable human and constant regions of the non-human mammal, but these could be quickly humanized, for example, in a cloning step. In addition, the in vivo efficacy of these chimeric antibodies: could be evaluated in these same animals. In one aspect, the human IgD-inserted VDJ region comprises, in germ line configuration, all V, De Je regions and intervening sequences derived from a human.
In one aspect, 800 - 1000 kb of the human IgD VDJ region is inserted into the IgH locus of the non-human mammal and, in one aspect, a 940, 950 or 960 kb fragment is inserted. Suitably, it includes asbases 105,400,051 to 106,368,585 of human chromosome 14 (all coordinates refer to NCBI36 for the human genome, ENSEMBL Re-lease 54 and NCBIM37 for the mouse genome, relative to the C57BL / 6J strain of mice) .
In one aspect, the inserted human IgH fragment consists of bases 105.400.051 to 106.368.585 of chromosome 14. In one aspect, the inserted human heavy chain DNA, such as the DNA formed by bases 105.400.051 to 106.368.585 chromosome 14, is inserted into the chromosome |
'there are 12 of mice, between the end of the J4 region and the Eu region of mice, suitably between the coordinates 114.667.091 and' 114.665.190, adequately at the coordinate 114.667.091. In one aspect, the inserted human VJ kappa region comprises, in a germ line configuration, all the V and J regions and intervening sequences derived from a human.
Suitably, this includes the bases 88.940.356 to 89.857.000 of human chromosome 2, with adequately around 917kb. In another aspect, the light chain VJ insert can comprise only the terminal groupings of segments V and segments J. Such an insert would have BR approximately 473 kb. 'In one aspect, human kappa light chain DNA, such as the human IgK fragment from bases 88,940,356 to 89,857,000 of human chromosome 2, is properly inserted into chromosome 6 of mouse 15, between the coordinates 70,673,899 and 70,675,515, suitably at position 70,674,734. Ú In one aspect, the human VJ lambda region comprises, in: germline configuration, all V and J regions and intervening sequences derived from a human. Suitably, it includes bases analogous to those selected for the kappa fragment, from human chromosome 2. All specific human fragments described above may vary in length and may, for example, be longer or shorter than the defined above, such as 500 bases, 1 KB, 2K, 3K, 4K, 5 KB, 10KB, 20 kKB, 30KB, 40 KB or 50 KB or more, suitably comprising all or part of the human V (D) J region , while preferably retaining the requirement for the final insert to comprise human genetic material encoding the entire heavy and light chain region, as appropriate, as described above.
In one aspect, the 5 'end of the human insert described above is enlarged in length. When the insert is generated in stages, the increase in extension, in this case, is usually in relation to the clone (5th) |
. upwards.
In one aspect, the 3 'end of the last human gene inserted, generally the last human J gene to be inserted, has less than 2. kb, preferably less than 1 KB of the human-mouse splicing region. In one aspect, the non-human mammal comprises part or all of the VJ region of the human light chain, as described in this report, but not the VJ region of the human lambda light chain. In another aspect, the genome comprises an insertion of genes V, D (heavy chain only) and J, as described in this report, in the heavy chain locus and a light chain locus, or in the heavy chain locus and the two light chain loci. Preferably, the genome is homozygous in one, or both, or in all three foci.
CC In another aspect, the genome can be heterozygous in one or more of the / oi, such as heterozygous for DNA encoding a chimeric antibody chain and native antibody chain (host cell). In one aspect, the genome can be heterozygous for DNA capable of encoding 2 different antibody chains of the invention, for example, comprising 2: different chimeric heavy chains or 2 different chimeric light chains.
In one aspect, the invention relates to a non-human mammal or cell and to methods for producing said mammal or cell, as described in this report, in which the inserted human DNA, such as the human IgH and / or VDJ region V, J light chain regions are found only in a single allele and not in the two alleles in the mammal or cell. In this respect, a mammal or cell has the potential to express the host antibody's endogenous heavy or light chain and a chimeric heavy or light chain.
In a further aspect of the invention, the human VDJ region or light chain VJ region is not used in its entirety, but parts of the equivalent human VDJ or VJ region, such as exons, from other species can be used, such as, one or more exons V, D or J of other species, or regulatory sequences of other species. In one aspect, se- |
. sequences used in place of human sequences are not human or mouse. In one aspect, the sequences used can be rodent Í or primate, like chimpanzee. For example, 1, 2, 3, 4 or more or all J regions of a primate other than human can be used to substitute a 2,3,4or more or all exons in the VDJ / VJ region of cells and ' animals of the invention.
In an additional aspect, the inserted human DNA, such as the human IgD VDJ region and / or light chain VJ regions, can be inserted so that they are operationally linked in the genome with a constant mu region of a species not human, not mouse, like a rodent or primate sequence, just like a rat sequence. : Other species other than human and mouse, of which DNA elements can be used in the present invention, include Ú 15 rabbits, dromedaries, alpacas, camels and sharks. In one aspect, the inserted human DNA, such as the human VDJ or VJ region, is not operably linked to the mu endogenous sequence of the: host, but rather to a sequence one that does not belong to the host. The operational link adequately allows the production of an antibody heavy or light chain comprising the human variable region.
In one aspect, the inserted human DNA, such as the human IgH VDJ region (and / or light chain VJ regions), can be inserted into the host's chromosome together with the nucleic acid from constant region one, which is not the nucleic acid of constant region one of the host and is preferably a constant region one of a non-mouse or human species. Suitably, the inserted human DNA, such as the human VDJ region (and / or light chain VJ regions), is operatively linked to non-human, or mouse, mu and is capable of forming a chimeric antibody heavy or light chain . In another aspect, neither a mouse nor a human can be inserted into the host's chromosome in a genetic element separate from that of the variable human region, or |
. at a different location in the genome, suitably operationally linked to the variable region so that a chimeric antibody heavy or light chain can be formed.
In one aspect, the invention relates to a cell, or non-human mammal, whose genome comprises one or more human kappa light chain V regions of lg and one or more human J regions of light kappa chain of lg in upward direction to all or part of the human kappa constant region.
In another aspect, the invention relates to a cell, or a non-human mammal, whose genome comprises: one or more V regions. Ig lambda light chain human and one or more Ig lambda light chain J regions upwardly to all or part of the human lambda constant CJ region.
Suitably, the light chain VJ and C regions are able to form antibody chains in vivo capable of reacting specifically with an antigen. In one aspect of the invention, there is no non-human coding sequence in the inserted light chain region.
In such aspects, a human kappa and / or lambda region is inserted into the genome, in combination with the insertion of the heavy chain VDJ region, or part of it, upwards to the host heavy chain constant region as described in this report.
Accordingly, the non-human cell or mammal of the invention may comprise: (a) a plurality of human V IgH regions, one or more human D regions and one or more human J regions upwardly to the constant region of the mammal non-human host; and (b) one or more human kappa light chain V regions of lg and one or more human J regions of light kappa chain of lg upwardly encompassed part of the non-human kappa constant region, in which the non-human mammal is capable of produce a repertoire of antibodies having an antibody chain comprising a constant region |
. non-human mammal and a human region.
The non-human cell or mammal of the invention may comprise: (a) a plurality of human IgH V regions, one or more human D regions and one or more human J regions upwardly to the constant U region of the non-human mammal host; and one or more human lambda Ig light chain V regions and one or more human lambda Ig light chain J regions upwardly to the lambda constant region of the host non-human mammal; wherein the non-human mammal is capable of producing a repertoire of antibodies having an antibody chain comprising a constant region of a non-human mammal and a variable human region.
C Suitably, the insertion of human VJC light chain DNA, or part of it, as described above, is performed at the equivalent locus | 15 mouse.
In one aspect, human VJC kappa DNA is inserted or part of it in an immediately upward direction or: downward to the mouse VJC kappa region.
In one aspect, the human VJC lambda light chain region or part of it in an immediately upward or downward direction is inserted into the mouse VJC lambda region.
In one aspect, only the human VJC kappa locus is inserted.
Insertions can be made using the techniques described here and, accordingly, do not remove the host sequences from the genome.
In one aspect, the VJC sequences of the host non-human mammal can be inactivated in some way, by mutation, or inversion, or by inserting the DNA of the human variable region or by any other means.
In one aspect, the cell or non-human mammal of the invention may comprise an insertion of the complete human VJC region.
The DNA of the human kappa variable region could be inserted into the genome in a functional arrangement with a constant lambda region, for example, inserted upwards to a constant lambda region.
Alternatively, the human lambda variable region DNA could be inserted into a functional array with a kappa constant region, for example, |
. inserted upwards to a constant kappa region. In one aspect, one or more control sequences of the non-human mammal, such as the enhancer sequence (s), are maintained upward to the Mu constant region of the non-human mammal. no, properly in its native position with respect to the distance to the constant region.
In one aspect, one or more control sequences of the non-human mammal, such as enhancer sequence (s), are maintained downwardly to the constant region Mu of the non-human mammal, suitably in its native position with respect to respect to distance to.: constant region. In one aspect, a switch sequence (isotypic change) from a non-human mammal, suitably an endogenous switch sequence, is maintained upwards to the constant region of the human mammal, appropriately with respect to the distance to the region constant. Ú In such a location, the host's enhancer or switch: sequences are operational in vivo with the host region's sequence (s).
In one aspect, a switch sequence is not human, nor native to the non-human mammal, for example, in one aspect, a switch sequence of a non-human mammal is not a mouse or human switch sequence. The switch sequence can be, for example, a rodent or primate sequence, or a synthetic sequence. Specifically, the swifch sequence can be a rat sequence, when the non-human mammal is a mouse. For example, a mouse or human constant mu sequence can be placed under the control of a mouse or chimpanzee switch sequence, or another switch sequence, suitably capable of allowing switching of isotypes to occur in vivo. .
The cell or mammal of the invention can, therefore, comprise a human or non-human mammalian switch sequence and a |
. human or non-human mammal intensifier region or regions.
These can be ascending towards a constant human region: or a non-human mammal.
Preferably, the R control sequences are able to direct expression or, otherwise, control the production of antibodies comprising a constant region with which they are associated.
A considered combination is a mouse switch sequence with mouse enhancer sequences and mouse constant regions in a mouse cell.
In one aspect, the invention relates to a cell, preferably a non-human cell, or a non-human mammal comprising. an immunoglobulin heavy chain or light chain locus, containing DNA from 3 or more species.
For example, the cell or animal can understand the DNA of the constant region of the host cell, one or more human V, D or J coding sequences and one or more regions of | 15 non-human or host DNA that are capable of controlling a region of the immunoglobulin locus, such as a switch, promoter or enhancer sequence, which are capable of controlling expression. or the isotypic in vivo change in lg DNA.
In one aspect, the cell belongs to or the animal is mouse and additionally comprises human human lg dolocus DNA and, in addition, a non-mouse DNA sequence, such as a mouse DNA sequence, capable of regulating the mouse or human DNA.
In another aspect, the invention relates to a cell, preferably a non-human cell, or a non-human mammal comprising — an immunoglobulin heavy chain or light chain / containing DNA of 2 or more different human genomes.
For example, it could comprise heavy chain V (D) J sequences, from more than one human genome, in a heavy or light chain, or heavy chain VDJ DNA from one genome and network chain VJ sequences. a different genome.
In one aspect, the invention relates to a fragment of DNA or a non-human cell or mammal comprising a p-chain locus |
. immunoglobulin output or part thereof, containing DNA from 2 or more species, in which one species contributes a non-coding region, such as a regulatory region, and the other species with coding regions,. as V, D, J or constant regions.
In one aspect, the human promoter and / or control elements that are associated with the different human V, D or J regions are maintained in the mouse genome.
In an additional aspect, one or more of the promoting elements, or other control elements, of human regions, such as human WV regions, are optimized to interact with the mechanism. transcription of a non-human mammal.
Suitably, a human coding sequence can be brought under the control of an appropriate promoter from a non-human mammal, which allows human DNA to be efficiently transcribed into the non-human animal cell 15.
In one aspect, the human region is a human V region coding sequence, and a human V region is brought under the control of a non-human mammalian promoter. . The functional replacement of a promoter or other human control regions by a non-human mammal promoter or control regions can be accomplished by using recombineering (genetic engineering) or by other recombinant DNA technologies, to insert a part of the human region of lg (as human V region) in a vector (as a BAC) containing a non-human Ig region.
The recombinant recombinant ringing technique adequately replaces a portion of non-human DNA (for example, mouse) with the human Ig region and thereby puts the human Ig region under the control of the promoter or another mammalian control region. not human.
Suitably, the human coding region of a human V region replaces a coding sequence for the mouse V region.
Suitably, the human coding region of a human D region replaces a coding sequence for the mouse D region.
Suitably, the human coding region of a human J region replaces a coding sequence for the J region of ca- |
'mundongo.
In this way, V, D or J regions can be placed under the control of a non-human mammalian promoter, such as a mouse "promoter.: In one aspect, the only human DNA inserted into the mammalian cell or the animal does not human are the regions encoding V, D or J, and 'these are placed under the control of the host's regulatory sequences or other sequences (not human or host). In one respect, the reference to human coding regions includes human introns and exons or, in another aspect, simply exons and non-introns, which can be in the form of cDNA.: Alternatively, it is possible to use recombineering or other recombinant DNA technologies to insert a promoter or other region of non-human mammalian Co-control (for example, mouse), as a promoter for region V, in a BAC containing a human Ig region.
The recombineering stage then places a portion of human DNA under the control of the promoter or another mouse control region. : The approaches described here can also be used: to insert some or all of the V, D and J regions of the human heavy chain upwards to a constant region of light chain, instead of upwards to the constant region of the heavy chain.
Likewise, some or all of the human V and J light chain regions can be inserted upwards to the constant region of the heavy chain.
The insertion can be in the endogenous focus of the constant region, for example, between the endogenous constant region and the J, and it can be of some or all of the V, D ouy genes only, excluding promoter or enhancer sequences, or it may be some or all of the V, D or J genes with one or more or all of the respective promoter or enhancer sequences.
In one aspect, the complete repertoire of fragments V, D or J in germ line orientation can be inserted upwards and in a functional arrangement with a constant region of the host.
Accordingly, the present invention allows V and / or D and / or J regions of a human or any species to be inserted into a |
. chromosome of a cell of a different species that comprises a constant region, allowing the expression of a chimeric U antibody chain. . In one aspect, the invention only requires that some human variable region DNA be inserted into the genome of a non-human mammal in an operational arrangement with some or all of the constant region of the human heavy chain in the endogenous / ocus region of the constant region. heavy chain in such a way that an antibody chain can be produced. In this aspect of the invention and when human light chain DNA is additionally inserted, the light chain DNA insertion can be in the form. a fully human construct, having human variable region DNA and human constant region DNA, or having human Ss variable region DNA and constant region DNA from a non-human species, nor from the host. Other variations are also possible, such as insertion of the human light chain variable region and the constant region of the host genome. In addition to being inserted, said light chain transgenes need not be in the equivalent endogenous locus, but can be in: anywhere else in the genome. In this hypothesis, the cell or mammal can produce chimeric heavy chains (comprising human variable region DNA and mouse constant region DNA) and light chains comprising human variable and human constant DNA. Therefore, in one aspect of the invention, the DNA of the human variable region lambda and / or kappa can be inserted upwards to the endogenous locus, or downwards, or, in fact, on a chromosome different from the locus endogenous, and inserted with or without constant region DNA.
As well as insertion of human light chain DNA upwardly into the constant region of the host non-human mammal, an additional aspect of the invention relates to the insertion of one or both human variable chain regions downwardly to the region contained in the endogenous focus or elsewhere in the genome.
In general, the insertion of human variable region DNA into or |
. close to the equivalent endogenous locus in the recipient genome, it is preferred, for example, within 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 kb of the limits (in "upward or downward") of a / ocus therefore, in one aspect, the invention may refer to a non-human or human cell whose genome comprises: '(a) a plurality of human V IgH regions, one or more human D regions and one or more human J regions upward to the host non-human mammal constant region, and (b) one or more human Ig kappa light chain V regions and one or more human Ig kappa light chain J regions and / or, one or more human lambda light chain V regions of lg and one or more human lambda light chain regions of lg; CU in which the non-human mammal is capable of producing a repertoire of chimeric antibodies, or chains light or heavy chimeric, having a non-human mammal constant region and a human variable region at.
In a specific aspect, the genome of the non-human cell or mammal comprises: BR a plurality of human V regions of IgH, one or more human D regions and one or more human J regions in an upward direction to the constant region of the non-human mammal host; one or more human kappa light chain V regions of lg and one or more human J regions of light chain kappa of lg upward to the kappa constant region of the host non-human mammal, and one or more human V regions of light chain Ig lambda and one or more human lambda light chain J regions of lg downwards to the host lambda constant region of the non-human mammal host, optionally in which the human lambda variable region can be inserted downwards to the host lambda endogenous locus in operational linkage with a human lambda constant region such that the mammal or non-human cell can produce fully human and chimeric heavy antibody chains.
In a different aspect of the invention, the use of |
- invention allows a locus to be built in stages by sequential insertions and, thus, allows the insertion of human variable region DNA or non-human constant region DNA in any suitable location in the genome of a cell of non-human host.
For example, methods of the invention can be employed to insert human immunoglobulin variable 'region DNA along with constant region DNA from the host genome anywhere in the genome of a non-human host cell, enabling a chain antibody antibody is produced from a site other than the heavy endogenous region.
Any construct contemplated above human heavy chain or BR light chain DNA can be inserted at any desired position in the genome of a non-human host cell using the techniques described herein.
The present invention therefore also relates to cells and mammals with genomes comprising such inserts.
The invention also relates to a vector, such as BAC, comprising a human V, D or J region in functional arrangement with a non-human mammalian promoter, or other control sequence, so that the expression of the human V, D or J region is under the control of the non-human mammalian promoter in a non-human mammalian cell, such as an ES cell, especially once inserted into the genome of this cell.
The invention also relates to cells and mammals containing said cells, these cells or mammals having a human V, D or J region in functional arrangement with a non-human mammalian promoter, or another control sequence, so that the expression of the human V, D or J region is under the control of the non-human mammalian promoter in the cells or mammal.
In general, one aspect of the invention therefore relates to a non-human mammalian host cell capable of expressing a human V, D or J coding sequence under the control of a promoter or host control region, the expression capable of producing a humanized antibody having a human variable domain and a con-
- amount of non-human mammal. In one aspect, the invention relates to a cell, such as a non-mammalian cell, as an ES cell, whose genome comprises: (a) a plurality of human IgH V regions, one or more human D regions and one or more human J regions upward to the constant I region of the host non-human mammal; and (b) optionally one or more human Ig kappa light chain V regions and one or more human kappa light chain J regions of lg upwardly to the kappa constant region of the host non-human mammal and one or more human chain V regions light lambda of lg and one or BR plus human J regions of light lambda of lg in an upward direction to the lambda constant region of the host non-human mammal; - In another aspect, the invention relates to a cell, such as non-human mammalian cells, such as ES cells, whose genome comprises: (a) a plurality of human Kappa light chain V regions of lg and one or more human kappa light chain regions of lg upward to the kappa constant region of the host non-human mammal and / or a plurality of human lambda light chain regions of lg and one or more human regions of Ig light lambda chain upward to the lambda constant region of the host non-human mammal; and (b) optionally one or more human V regions of IgH, one or more human D regions and one or more human J regions upwardly to the constant region of the host non-human mammal.
In one aspect, the cell is an ES cell capable of growing into a non-human mammal and producing a repertoire of antibodies, which are chimeric, said chimeric antibodies having a non-human mammal constant region and a human variable region. Optionally, the cell's genome is modified to prevent the expression of antibodies totally specific to the host species.
In one aspect, the cell is an induced pluripotent stem cell (iPS cell). |
. In one aspect, the cells are isolated non-human mammalian cells. 'In one respect, a cell described in this report is preferable. a non-human mammalian cell.
The invention also relates to a cell line that is cultured or otherwise derived from cells as described in this report, including immortalized cell line.
The cell line can comprise inserted human V, D or J genes, as described here, either in germ line configuration or after rearrangement following maturation in vivo. The cell can be immortalized by fusion with a cell tumor. to provide an antibody-producing cell or cell line, or it can be produced by direct cell immortalization. The present invention also relates to vectors for use in the invention.
In one respect, such vectors are BACs (bacterial artificial chromosomes). It will be appreciated that other cloning vectors can be used in the invention and, therefore, reference to BACs in this patent application can be understood as referring in general to any suitable vector. - In one aspect, BACs used to generate human DNA to be inserted, such as VDJ or VJ, are trimmed so that, in the final human VDJ or WVJ region, or part of it, in the non-human mammal, none sequence is duplicated or lost when compared to the original human genomic sequence.
In one aspect, the invention relates to a vector comprising an insert, preferably including a region of human DNA derived from some of the human VDJ or VJ loci, flanked by DNA not belonging to that Jocus.
The flanking DNA can comprise one or more selectable markers or one or more site-specific recombination sites.
In one aspect, the vector comprises 2 or more, such as 3, heterospecific and incompatible sites of site-specific recombination.
In one aspect, the specific recombination sites can be loxP sites, or variants thereof, or FRT sites or variants of this.
In one aspect, the vector comprises one or more transposon ITR sequences (terminal repeat |
. inverted). In one aspect, the non-human animals of the invention suitably do not produce fully humanized antibodies.
In one aspect-. However, this is due to the fact that DNA from the human constant region has not been inserted.
Alternatively, there is no human constant region DNA in the gene, but capable of forming an antibody in conjunction with the inserted human variable region DNA component, for example, due to mutation within any human constant region DNA. or the distance from any human constant region DNA and human variable region DNA.
In one aspect, human DNA from the light BR chain constant region can be included in the cell genome, such that a fully human antibody lambda or kappa chain could generate, but that CC was only able to form an antibody with a chain heavy and does not produce a fully human antibody having human constant variable regions.
In one aspect, the genome of the non-human mammal is modified to prevent the expression of fully specific antibodies to. host species.
Antibodies totally specific to the host species are antibodies that have variable and constant regions derived from the host organism.
In this context, the term "specific" is not intended to refer to the binding of antibodies produced by the cells or animals of the invention, but rather to the origin of the DNA encoding these antibodies.
In one aspect, the genome of the non-human mammal is modified to prevent the expression of native antibodies (fully specific for the host species) in the mammal by inactivating all or part of the non-human mammal's Ig loci. .
In one respect, this is achieved by reversing all or part of the VDJ or VJ region of the non-human mammal, optionally by inserting one or more specific recombinase sites into the genome and then using these sites for excision or inversion, mediated by recombinase, of all or part of the non-human mammalian Ig locus.
In one aspect, an in- |
. a double version can be used, the first to move and move the V (D) Js away from the endogenous locus and then a more local inversion than the positions in the correct orientation. In one aspect, a single loxP site is used for-. to invert the VDJ region of the non-human mammal to a centromeric or locustomeric locus.
In one respect, the genome of the non-human mammal in which human DNA is inserted comprises endogenous V, (D) and J regions, and the endogenous sequences have not been deleted.
The invention comprises a method for inserting multiple DNA fragments into a target DNA, suitably to form a contiguous insertion in which the inserted fragments are joined directly without intervening sequences. The method applies especially to the insertion of a large fragment of DNA into a host chromosome that can be performed in stages.
In one aspect, the method comprises inserting a first DNA sequence into a target, the sequence having a portion of | Vector DNA and a first sequence of interest (X1); inserting - a second DNA sequence into the vector portion of the first sequence, the second DNA sequence having a second sequence of interest (X2) and a second vector portion; and then excising any vector DNA sequence, separating X1 and X2, to provide a contiguous X1X2 or X2X1 sequence within the target. There is optionally the insertion of one or more additional DNA sequences, each DNA sequence having an additional sequence of interest (X3, ...) and an additional portion of the vector portion of the preceding DNA sequence to construct a fragment contiguous DNA in the target.
The DNA target for insertion of the first DNA sequence may be a specific site or any point in the genome of a given cell.
The general method is described in this report in relation to the insertion of elements from the human VDJ region, but it can apply to the insertion of any region of DNA, derived from any organism and, specifically, to |
. insertion of large fragments of DNA of> 100 kB, such as 100 - 250 kb, or even larger, such as that of the TCR or HLA. Characteristics and approaches described in this patent application regarding the insertion of VDJ po-. can also be applied to any of the methods described. In one aspect, the inserted DNA is human DNA, just like the human VDJ or VJ region, it is built into the genome of a cell, such as ES cell, in stages, using 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20 or more separate inserts for each heavy chain or light chain region. The fragments are properly inserted into the same or substantially the same cell locus, for example, ES cell locus, um. after another, to form the complete VDJ or VJ region, or part of it. The present invention also relates to non-human cells and animals, - comprising process intermediates, whose genomes can comprise only a partial VDJ region, such as only human variable region DNA.
In a further aspect, the method for producing a transgenic non-human mammal comprises the insertion of VDJ or VJ hu- regions. upward to the constant region of the host non-human mammal inserted in stages of multiple fragments by homologous recombination, preferably using an iterative process. Suitably, approximately 100 KB fragments of the human VDJ and VJ locus are inserted, suitably to integrate or complete a VDJ or VJ region after the final iteration of the insertion process, as described in this patent application.
In one aspect, the insertion process begins at a site where an initiation cassette has been inserted into the genome of a cell, such as an ES cell, creating a unique region for targeting. In one aspect, the initiation cassette is inserted into the heavy chain locus of the non-human mammal, for use in inserting human heavy chain DNA. Likewise, an initiation cassette is inserted into the light chain locus of the non-human mammal, for use in inserting human VJ region DNA. The initiation cassette adequately comprises the chain sequence |
. main element of a vector with which a vector having a human DNA fragment in the same main chain sequence can recombine to insert human DNA into the cell's genome of the cell (for example, ES) and, accordingly , a selection marker, such as a negative selection marker. Suitably, the vector main chain sequence is that of a BAC library to allow BACs to be used in the construction of ES and mammalian cells. The vector main chain sequence can, however, be any sequence that serves as a target site in which a homologous sequence can be inserted, for example, by homologous recombination and RMCE, and preferably not is DNA encoding. any VDJ or constant region. In one aspect, insertion of the first DNA fragment into the * initiation cassette is followed by insertion of a second DNA fragment into a portion of the first DNA fragment, suitably a part of the vector's main strand of the second DNA fragment. In one aspect, an inserted DNA fragment comprises a part of the human VDJ region flanked by 5 'and / or 3' sequences that do not belong to the re-. human VDJ region. In one aspect, the 5 'and / or 3' flanking sequences can contain each or more selectable markers or be able to create a selectable system when inserted into the genome. In one aspect, one or both flanking sequences can be removed from the genome in vitro or in vivo, after insertion. In one aspect, the method comprises inserting a DNA fragment followed by selecting the two ends, 5 'and 3', of the inserted fragment flanking the human VDJ DNA. In one aspect, iterative insertion is carried out by inserting DNA fragments at the 5 'end of the previous inserted fragment, and in this aspect, there may be in vivo deletion of the vector DNA that separates the inserted sequences from human DNA, to create a sequence continuous human DNA.
In one aspect, human VDJ DNA can be inserted into a genome without any flanking DNA being left in the genome, for example, by transposase-mediated DNA excision. A transpo- |
+ suitable sase is Piggybac transposase.
In one aspect, the first human variable region fragment 'is inserted by homologous recombination in the sequence of the x initiation cassette main chain and then subsequent DNA removal of any negative selection marker and the initiation cassette is performed by combination of recombinase target sequences, such as FRT, using FLPase expression in this example. In general, repeated targeted insertions in the main chain initiation sequence (eg, BAC) and subsequent removal by rearrangement between recombinase target sequences are repeated to construct the entire human VDJ region in a direction - ascending to the non-mammalian constant region hostess. In one aspect, a selectable marker or system can be "used in the method. The marker can be generated when inserting a: DNA fragment into a genome, for example, forming a marker - selectable in conjunction with a DNA element already present in the genome. : In one aspect, the cell's genome of the cell (eg, ES) does not contain 2 identical selectable markers at the same time during the process. It can be seen that the iterative process of insertion and selection can be performed using only 2 markers different selection, as described in the examples of this patent application, and, for example, the third selectable marker may be identical to the first marker, since, when the third vector fragment is inserted, the first vector fragment and the first marker will have already been removed.
In one respect, a correct insertion event is confirmed before proceeding to the next step in any multi-step cloning process, for example, by confirming the BAC structure using high density genomic arrangements to track cells ES and identify those with intact BAC inserts, by sequencing and PCR verification.
In one aspect, the method employs site-specific recombination to insert one or more vectors into the genome of a cell, such as an ES cell. Site-specific systems for recombinase are well co- |
. known in the art and may include Cre-lox and FLP / FRT or combinations thereof, in which recombination occurs between 2 sites having sequence homology.
. Suitable BACs are provided by the Sanger center, see "A genome-wide, end-sequenced 129Sv BAC library resource for tar-: geting vector construction". Adams DJ, Quail MA, Cox T, van der Weyden L, Gorick BD, Su Q, Chan WI, Davies R, Bonfield JK, Law F, Humphray S, Plumb B, Liu P, Rogers J, Bradley A. Genomics. 2005 Dec; 86 (6): 753-8. E-pub 2005 Oct 27. The Wellcome Trust Sanger Institute, Hinxton, Cambridge-shire CB10 1SA, United Kingdom. BACs containing human DNA are available. also used, for example, by Invitrogen. A suitable library is described in Osoegawa K et al., Genome Research 2001.11: 483-496. ”In one aspect, a method of the invention specifically comprises: i 15 (1) insertion of a first DNA fragment into a non-human ES cell, the fragment containing a first portion of human DNA from the VDJ region or VJ and a first vector portion containing a first selectable marker; (2) optionally, the deletion of part of the first vector portion; (3) the insertion of a second DNA fragment into a non-human ES cell containing the first DNA fragment, the insertion occurring within the first vector portion, the second DNA fragment containing a second portion of the VDJ or VJ region human and a second vector portion containing a second selectable marker, (4) the deletion of the first selectable marker and the first vector portion, preferably by the action of a recombinase enzyme; (5) the insertion of a third DNA fragment in a non-human ES cell containing the second DNA fragment, the insertion occurring within the second vector portion, the third DNA fragment containing a third portion of the VDJ or VJ region and a third vector portion containing a third selectable marker, (6) the deletion of the second selectable marker and the second portion of |
. vector; and (7) the iteration of the insertion and deletion steps, as needed, for] the fourth fragments and additions from the human VDJ or VJ regions, as | necessary to produce an ES cell with a part or all of the human WVDJ or WVJ region inserted as described herein and, accordingly, to remove all vector portions within the ES cell genome.
In another aspect, the invention comprises: (1) insertion of DNA, forming an initiation cassette in the genome of a cell; (2) insertion of a first DNA fragment in the initiation cassette, o. first DNA fragment comprising a first portion of human DNA and a first vector portion containing a first selectable marker or generating a selectable marker at insertion; (3) optionally, removing part of the vector DNA; (4) insertion of a second DNA fragment into the vector portion of the first DNA fragment, the second DNA fragment containing a second portion of human DNA and a second vector portion, the second portion of vector containing a second selectable marker, or generating a second selectable marker upon insertion; (5) optionally, removing any vector DNA to allow the first and second human DNA fragments to form a contiguous sequence; and (6) iterating the steps of inserting human VDJ DNA and removing vector DNA, as needed, to produce a cell with all or part of the human VDJ or VJ region sufficient to be able to generate a chimeric antibody in conjunction with a constant region of the host, in which the insertion of one or more or all of the DNA fragments uses site-specific recombination.
In one aspect, the non-human mammal is able to generate a diversity of at least 1 X 10 different combinations of functional chimeric immunoglobulin sequences.
In one aspect, targeting is performed on ES |
. riveted from the C57BL / 6N, C57BL / 6J, 12985 or 129Sv strain of mice. 'In one respect, non-human animals, such as mouse-. are generated in a background deficient in RAG-1 or another suitable genetic background that prevents the production of mature B and T lymphocytes from the host.
In one aspect, the non-human mammal is a rodent, suitably a mouse, and cells of the invention, are rodent cells or ES cells, suitably mouse ES cells.
The ES cells of the present invention can be used to gear animals using techniques well known in the art, which comprise injection of the ES cell into a blastocyte, followed by im-C planting of chimeric blastocytes in females to produce a litter that can be improved and selected for the presence of recombi- | 15 homozygous names having the required insertion. In one aspect, the invention relates to a chimeric animal consisting of tissue derived from ES cells and tissue derived from host embryo. In one aspect, the invention relates to animals with subsequent genetically altered generation, which include animals having homozygous recombinants for the VDJe / orVJ regions.
In a further aspect, the invention relates to a method for producing a specific antibody against a desired antigen, the method comprising immunizing a transgenic non-human mammal, as above, with the desired antigen and recovering the antibody (see, for example, example, Harlow, E. & Lane, D. 1998, 5th edition, Antibodies: A Laboratory Manual, Cold Spring Harbor Lab. Press, Plainview, NY; and Pasqualini and Rap, Proceedings of the National Academy of Sciences ( 2004) 101: 257-259). Suitably, an immunogenic amount of the antigen is released. The invention also relates to a method for detecting a target antigen, comprising detecting an antibody produced as above with a secondary detection agent that recognizes a part of this antibody.
In a further aspect, the invention relates to a method for |
. to produce a fully humanized antibody, comprising immunizing a transgenic non-human mammal as above with the desired antigen, recovering the antibody or cells expressing the antibody and, if so. Therefore, replace the non-human mammal constant region with a human constant region.
Standard DNA-level cloning techniques can be employed to replace the non-human mammalian constant region with an appropriate human constant region DNA sequence - see, for example, Sambrook, J and Russell, D. ( 2001, 3rd edition) Molecular Cloning: A Laboratory Manual (Cold Spring Harbor Lab.
Press, Plainview, NY). . In a further aspect, the invention relates to humanized antibodies and chains of antibodies produced in accordance with the present. invention, both in chimeric and fully humanized form, and use of said antibodies in medicine.
The invention also relates to a | 15 a pharmaceutical composition comprising these antibodies and a pharmaceutically acceptable carrier or other excipient.
In this specification, chains of antibodies containing se-. human sequences, such as human-non-human chimeric chains of antibodies, are considered humanized due to the presence of the human protein coding region / regions.
Fully humanized antibodies can be produced from DNA encoding a chimeric chain of antibodies of the invention using standard techniques.
Methods for generating monoclonal and polyclonal antibodies are well known in the art, and the present invention relates to polyclonal and monoclonal antibodies to chimeric or fully humanized antibodies produced in response to antigenic exposure in non-human mammals of the present invention.
In yet another aspect, chimeric antibodies or chains of antibodies generated in the present invention can be manipulated, suitably at the DNA level, to generate molecules with antibody-like properties or structure, such as a human variable region from a ca - heavy or light hate without constant region, for example, an antibody of |
- domain; or a human variable region with any constant region starting from the heavy or light chain of the same or different species; or 'human variable region with a constant region that does not occur naturally -. mind; or human variable region along with any other fusion partner. The invention relates to all such chimeric antibody products, derived from chimeric antibodies identified in accordance with the present invention. In a further aspect, the invention relates to the use of animals of the present invention in the analysis of the likely effects of drugs and vaccines in the context of a repertoire of quasi-human antibodies.
- The invention also relates to a method for identification or validation of a drug or vaccine, the method comprising releasing the vaccine or drug to a mammal of the invention and monitoring one or more of: a: immune response, the profile safety, the effect on disease.
The invention also relates to a kit comprising an antibody: antibody or antibody derivative, as described in this patent application, and instructions for using this antibody or a suitable laboratory reagent, such as buffer, antibody detection reagent.
In certain aspects, the invention relates to: A non-human mammal whose genome comprises: (a) the human VDJ region of IgG upwardly to the constant region of the host non-human mammal; and (b) Ig kappa light chain human V and J regions upward to the host non-human mammalian Kappa constant region and / or Ig lambda light chain human Ve J regions upward to the region lambda constant of the host non-human mammal; wherein the non-human mammal is capable of producing a chimeric antibody repertoire having a non-human mammal constant region and a human variable region, and optionally where the non-human mammal genome is modified to prevent the expression of antibodies entirely specific to the host species.
|
. A non-human mammalian ES cell whose genome comprises: (a) the human IgH V, D and J region upwardly to a “non-human mammal constant” region; and (b) the human VeJ regions of the lg kappa light chain / ocus in an upward direction to the kappa constant region of the host non-human mammal, and / or the human V and J regions of the Ig lambda light chain locus in upward to the lambda constant region of the host non-human mammal; in which the ES cell is able to grow in a non-human mammal, managing to produce a repertoire of antibodies that are chimeric, having a constant region of non-human mammal and a variable region - human. : A method for producing a transgenic non-human mammal capable of producing a chimeric antibody repertoire, antibodies having a non-human mammal constant region and a human variable region, the method comprising inserting into the genome of a non-human mammalian ES cell , by homologous recombination, (a) the human IgD VDJ region upward to the constant region of the host non-human mammalian heavy chain and (b) the human IlgL VJ region for lambda or kappa chains upward to the constant region of lambda or kappa chain of the host non-human mammal, respectively, so that the non-human mammal is able to produce a chimeric antibody repertoire having a non-human mammal constant region and a human variable region, in which the steps (a ) and (b) can be performed in any order and each of steps (a) and (b) can be performed in stages or in a single stage.
In one aspect, the insertion of human VDJ or VJ regions in an upward direction to the constant region of the non-human mammal is accomplished by insertion in stages of multiple fragments by homologous recombination. |
. In one aspect, step insertions begin at a site where an initiation cassette has been inserted into the genome of an ES cell providing a single target region, consisting of a sequence of ca-. main BAC test and a negative selection marker. In one aspect, the first human variable region fragment Ú is inserted by homologous recombination into the BAC main chain sequence of the initiation cassette and said negative selection marker and initiation cassette are subsequently removed by recombination between recombinase target sequences. .
In one respect, targeted inserts repeated in the sequence. of initiation of the BAC main chain and subsequent removal of the main chain by rearrangement between recombinase target sequences is repeated o to construct the entire human VDJ region upwardly to the host non-mammalian constant region.
Other aspects include:. A method for producing a specific antibody against a desired antigen, the method comprising immunizing a non-human mammal, as described herein, with the desired antigen and recovering the antibody or an antibody-producing cell.
A method for producing a fully humanized antibody, comprising immunizing a non-human mammal, as described herein, and then replacing the non-human mammal constant region of an antibody specifically reactive with the antigen with a human constant region, suitably engineered of the nucleic acid encoding the antibody.
A method, cell or mammal as described in this report, in which a human DNA sequence from coding region is in functional arrangement with a non-human mammalian control sequence, such that DNA transcription is controlled by the sequence control of the non-human mammal. In one aspect, the human coding region of regions V, D or J is in functional arrangement with a mouse promoter sequence.
|
. The invention also relates to a humanized antibody produced in accordance with any methods described in this report and the use
'of a humanized antibody thus produced in medicine. . It will be understood that specific embodiments described in this patent application are shown by way of illustration and not as limitations of the invention.
The main features of this invention can be used in various embodiments without departing from the scope of the invention.
Those skilled in the art will recognize, or be able to verify, using no more than the routine study, numerous equivalents to the specific procedures described in this report.
Such - equivalents are considered to fall within the scope of this invention and are covered by the claims.
All publications and patent applications mentioned in this patent application are indicative of the level of ability of those skilled in the state of the art to which this invention belongs.
All publications and patent applications are hereby incorporated by reference into this patent application to the same extent as they would if each publication or patent application had been specifically and individually indicated to be incorporated by reference.
The use of the word "one" or "one" when used in conjunction with the term "comprising" in the claims and / or in the specification can mean "one," but it is also compatible with the meaning of "one or more", "at least one" and "one or more than one". The use of the term "or" in the claims is used to mean "and / or" unless explicitly indicated to refer to alternatively only or the alternatives are mutually exclusive, although the descriptive report supports a definition that refers only to alternatives and "and / or." Throughout this patent application, the term "around" is used to indicate that a value includes the inherent variation of error for the device, the method being used to determine the value or variation between subjects in study.
In this specification and in the claims, the words "comprising" (and any form of understanding, such as "understand" and "understand"), "having" (and any form of having, such as "have" and |
. "has"), "including" (and any form of including, such as "includes" and "include") or "containing" (and any form of containing, such as "contains" and "contain") Ú are inclusive or open and they do not exclude elements or method steps. additional, not stated.
The term "or combinations of these" in this specification refers to all permutations and combinations of the listed items that precede the term. For example, "A, B, C or combinations of these" is intended to include at least one of: A, B, C, AB, AC, BC or ABC, and if order is important in a given context, also BA, CA, CB, CBA, BCA, ACB, BAC or CAB. Continuing with this example, I expressly included it. das are combinations that contain repetitions of one or more item or term, such as BB, AAA, MB, BBC, ASABCCCC, CBBAAA, CABABB and so on. One skilled in the art will understand that there is typically no limit on the number of items or terms in any combination, unless otherwise evident from the context.
Any part of this specification can be read in combination with any other part of the specification, unless - otherwise evident from the context.
All the compositions and / or methods that have been described and are claimed in this patent application can be produced and executed without undue experimentation, in the light of this specification. Although the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those skilled in the art that variations may be applied to the compositions and / or to the methods and in the steps or in the sequence of steps of the method described here without departing from the concept, spirit and scope of the invention. All such substitutes and modifications evident to those skilled in the art are considered to fall within the spirit, scope and concept of the invention as defined by the appended claims.
The present invention is described in more detail in the following non-limiting Examples. Example 3 describes experimental data |
. such as have been obtained and reinforce the proof of concept of certain aspects of the invention, while Example 1 and 2 provide detailed guidance for Ú one skilled in the art to practice the claimed invention. R Example 1 Global strategy 'A mouse model of the invention can be achieved by inserting -960 kb from the human heavy chain locus, containing all V, D and J regions upward to the mouse constant region and 473 kb from the human kappa region upwards to the constant region of the mouse. Alternatively, or in tandem, the human lambda region is inserted upwards to the constant mouse region. This insertion is achieved by genetic targeting in ES cells, using techniques well known in the prior art. The high-fidelity insertion of intact V-D-J regions at each locus in its native (wild type) configuration is adequately accomplished by inserting human artificial bacterial chromosomes (BACs) into the locus. Suitably, the BACs are cut and trimmed so that, - at the final locus, there is no duplicated or lost sequence when compared to the original. This adjustment can be accomplished by recombineering. The relevant human BACs, adequately trimmed, covering these / oci have an average size of 90 kb.
In one approach, the full complement of human D and J elements, as well as seven or eight human V regions are covered by the first BACs to be inserted into the experimental insertion scheme described below. The first BACs to be inserted into the IgH and IgK loci may contain the following V IgH regions: V6-1, VII-1-1, V1-2, VIII-2-1, V1- 3, V4-4, V2 -5 and IgK: V4-1, V5-2, V7-3, V2-4, V1-5, V1-6, V3-7, V1-8.
Suitably, the performance of each locus is assessed after the insertion of the first BACs, using chimeric mice, in addition to after each subsequent addition of BAC. See below for a detailed description of this performance test.
Nine additional BAC inserts will be required for the lo- |
. IgH and five for IgK to obtain the full complement of human V regions, covering all 0.96 Mb and 0.473 Mb of IgH and IgK,
Ú respectively. . Not all BACs will retain their wild type configuration when inserted into the ES cell genome.
Therefore, high-density genomic arrays are used to track ES cells and identify those with intact BAC inserts (Barrett, MT, Scheffer, A., Ben-Dor, A., Sampas, N., Lipson, D., Kincaid, R., Tsang, P., Curry, B., Baird, K., Meltzer, PS, et al. (2004) .Comparative genomic hybridization using oligonucleotide microarrays and total genomic DNA.
Proceedings of the National Academy of. Sciences of the United States of America 101, 17765-17770.). This screening also makes it possible to identify and select against ES clones in which the ES cell genome is compromised and, therefore, unable to populate the germline of chimeric animals.
Other tools i 15 —genomics suitable to facilitate this assessment include sequencing
: and PCR verification.
Therefore, in one respect, the correct structure of the BAC is - confirmed before proceeding to the next step.
It is implied, from the description above, that in order to completely build the 90 kb BACs / ocicom, it is necessary to perform at least 10 steps of targeting for IgH and 5 steps for IgK.
Mice with locus of lgl. can be generated in a manner similar to the IgK locus.
Additional steps are necessary to remove the selection markers required to support the targeting of the gene.
Since these ma- —nipulations are performed in ES cells in stages, in one aspect, the germline transmission capacity is retained throughout this process.
Maintaining the performance of Es cell clones through multiple rounds of manipulation without the need to test the germ line potential of the ES cell line at each stage may be important in the present invention.
The cell lines currently in use for the global knockout (silencing) projects KOMP and EUCOMM have been modified |
: stayed twice before they were used in this project, and their germline transmission rates have not changed from the progenitor cells: these strains are publicly available, see. www.Komp.org and www.eucomm.ord ). This cell line, called —JMB, can generate mice 100% derived from Es cells under the published culture conditions (Peititt, SJ, Liang, Q., Rairdan, XY, Moran, JL, Prosser, HM, Beier, DR, Lloyd, KC, Bradley, A., and Skarnes, WC (2009). Agouti C57BL / 6N embryonic stem cells for mouse genetic resources. Nature Methods). These cells demonstrated the ability to reproducibly contribute to somatic tissue and germline lineage of animals. more chimeric, using standard mouse ES cell culture conditions. This ability can be found with cells cultured C in standard cell line feeder (SNL) and even without a feeder, cultured only in tissue culture plates coated with gelatin.
A specific underline, JMBA3, maintained the ability to populate the: chimera germ line after several rounds of subcloning. Intense genetic manipulation through, for example, homologous recombination - as would be the case in the present invention - cannot compromise the pluripotency of cells. The ability to generate chimeras with a percentage of tissue derived from ES cells has other advantages. Firstly, high levels of chimerism correlate with germline transmission potential and serve as a substitute test for cell line transmission, requiring only 5 to 6 weeks. Second, as these mice are 100% derived from ES cells, the constructed / oci can be directly tested, eliminating the delay caused by genetic improvement. It is possible to test the integrity of the new lg loci in the chimeras since the host embryo will be derived from animals that are mutants for the RAG-1 gene as described in the following section.
- Another cell line that can be used is an H-PRT-ve cell line, such as AB2.1, described in "Chromosome engineering in mice", Ram-frez-Solis R, Liu P and Bradley A, Nature 1995; 378 ; 6558; 720-4.
|
. Complementation of RAG-1 While many clones will generate mice 100% derived from ES, some will not.
Therefore, at every stage, mice are generated with a RAG-1 deficiency background. In this way, mice are provided with 100% ES-derived Be T cells that can be used directly for immunization and antibody production.
Cells with a RAG-2 deficient background, or a combined RAG-1 / RAG-2 deficiency background can be used, or equivalent mutations in which the mice produce only B cells and / or T cells derived from ES cells. - In order for only the IgH or IgK human-mouse loci to be active in these mice, the IgH and CG IgK human-mouse loci can be constructed in a cell line in which an allele of: IgH or IgK locus has already been inactivated .
Alternatively, inactivation of the host's lg locus, such as the focus of IgH or IgK, can be performed. after insertion.
Mouse strains with mutations in the RAG-1 gene are - immunodeficient since they lack mature B or T lymphocytes (US 5 859 307). T and B lymphocytes only differentiate if the V (D) J recombination is appropriate.
Since RAG-1 is a key enzyme for this recombination, mice lacking RAG-1 are immune deficient.
If host embryos are genetically mutant homozygous for RAG-1, a chimera produced by injecting such an embryo will not be able to produce antibodies if the animal's lymphoid tissues are derived from the host embryo.
However, JM8 cells and AB2.1 cells, for example, generally contribute to over 80% of the chimeric animal's somatic tissues and would therefore normally populate lymphoid tissue.
JM8 cells have wild-type RAG-1 activity and, therefore, antibodies produced in the chimeric animal would be encoded by the genome constructed only with ES JM8 cells. Therefore, the chimeric animal can be exposed to an antigen by immunization and subsequently produce antibodies against that antigen.
This allows for one skilled in |
. technique to test the performance of human / mouse IgH and IgK loci, constructed as described in the present invention. See figures 19] and 20.
. Any technician skilled in the art would use the chimeric animal described to determine the extent of antibody diversity (see, for example, Harlow, E. & Lane, D. 1998, 5th edition, Antibodies: A Laboratory Manual, Cold Spring Harbor Lab Press, Plainview, NY). For example, the existence in the chimeric animal's serum of certain antibody epitopes could be verified by binding to the specific anti-idiotype antiserum, for example, in an ELISA assay. A person skilled in the art could also sequence the genomes of B-cell clones derived from the chimeric animal and compare that sequence with the jungle-like sequence to check the level of hypermutation, such as hypermutation indicative of maturation of antibodies.
A person skilled in the art would also use said chimeric animal to examine antibody function, in which said antibodies are encoded from the constructed Ig loci (see, for example, Harlow, E. & Lane, D. 1998, 5th edition, Antibodies: A Laboratory Manual, Cold Spring Harbor Lab. Press, Plainview, NY). For example, the antiserum could be tested for binding to an antigen, the antigen used to immunize the chimeric animal. Such an assessment could be carried out by an ELISA assay. Alternatively, any person skilled in the art could test antigen neutralization by adding the antisera collected from the appropriately immunized chimeric animal.
As is well known to those skilled in the art, positive results for any of these tests demonstrate the ability of the constructed Ig loci, the object of the present invention, to encode antibodies with human variable regions and constant mouse regions, said antibodies capable of to operate in the manner of wild-type antibodies.
Experimental Recombineering techniques for the production of vectors to be used in |
. homologous recombination in ES cells is described in, for example, WO09929837 and WO0104288, and the techniques are well known in the art.
In one respect, the recombineering of human DNA. occurs using BACs as a source of said human DNA.
Isolation of human BAC-DNA is carried out with Qiagen's BAC purification kit. 'The main chain of each human BAC will be modified by the recombineering technique in exactly the same or similar configuration to the BAC already inserted in the mouse IgH region.
The genomic insert of each human BAC will be cut and trimmed using the recombineering technique so that once the BACs are inserted, a continuous contiguous part. of the human V (D) J genomic region will form at the mouse IgH or IgK locus.
The BAC DNA will be transfected by electroporation, and the genotype will be carried out according to standard protocols (Prosser, HM ,, Rzadzinska, AK, Steel, KP, and Bradley, A. (2008). Mosaic complementation demonstrates a regulatory role for myosin Vila in actin dynamics of steerocilia.
Molecular and Cellular Biology 28, 1702-1712; Ramirez-Solis, R., Davis, A.C., and Bradley, A. (1993). Gene targeting in embryonic stem cells. - Methods in Enzymology 225, 855-878.). The recombineering method will be performed using the procedures and reagents developed by the laboratory of Pentao Liu and Don Court (Chan, W. ,, Costantino, N ,, Li, R., Lee, SC, Su, Q., Melvin , D., Court, DL, and Liu, P. (2007) .A recombineering based approach for high-throughput conditional knockout targeting vector construction.
Nucleic Acids Research 35, e64). These and other techniques for genetic targeting and recombination of chromosomal fragments derived from BAC in the genome of a non-human mammal, such as a mouse, are described in, for example,
http: /Avww.eucomm.org/information/targeting/e http: /NWwww.eucomm.org/information/publications.
Cell culture of cell lines derived from C57BL / 6N, such as male JM8 ES cells will follow standard techniques.
The JM8 ES cells have demonstrated competence in contributing intensively to somatic tissues and to the germline and are |
. used in major mutagenesis programs in mice in Sanger, such as EUCOMM and KOMP (Pettitt, SJ, Liang, Q., Rairdan, XY, Mo-: ran, JL, Prosser, HM, Beier, DR, Lloyd, KC, Bradley, A., and Skarnes,: WC (2009) Agouti C57BL / 6N embryonic stem cells for mouse genetic sources.
Nature Methods). ES cells of JM8 ES (1.0 X 107) will undergo ele- 'troporation (500 UF, 230 V; BioRad) with 10 pg of linearized human BAC DNA from | -Scel, Transfectants will be selected with Puromycin (3 pug / ml) or with G418 (150 pg / ml). The selection will start after 24 hours (with G418) or 48 hours (with Puromycin) of electroporation and will continue for 5 days.10 µg of linearized human BAC DNA can yield up to 500. colonies of Puromycin- or G418-resistant ES cells. Colonies of antibiotic-resistant ES cells will be collected in 96-well cell and culture plates for genotyping and identification of target clones.
Once identified, the target clones of mouse ES cells will be analyzed by Comparative Genomic Hybridization (CGH) in arrangements: as for the total integrity of the genome (Chung, YJ, Jonkers, J., Kitson, H., Fiegler, H., Humphray, S., Scott, C, Hunt, S., Yu, Y., Nishijima, |., Velds, A., N et al. (2004). A whole-genome mouse BAC microarray with 1-Mb resolution for analysis of DNA copy number changes by array comparative genomic hybridization Genome research 14, 188-196 and Liang, Q., Conte, N., Skarnes, WC, and Bradley, A. (2008). Extensive genomic copy number variation in embryonic stem cells.
Proceedings of the National Academy of Sciences of the United States of America 105, 17453-17456.). ES cells containing abnormal genomes do not contribute efficiently to the germline of chimeric mice.
The integrity of BACs will be examined by PCR amplification of each functional V gene known in the BAC.
For example, in one approach, the first BAC chosen for the IgH locus has 6 functional V genes.
In order to confirm the integrity of this BAC regarding the presence of these 6 IGH V genes, at least 14 pairs of PCR primers will be designed and used to PCR amplify the genomic DNA of the target ES cells.
The size and wild-type sequence of these fragments will ensure that the inserted BAC has not been rearranged
|
. tidy. . More detailed CGH will also confirm the integrity of the 'inserted BACs. For example, any technician versed in the subject could. use an aCGH oligo platform, which is developed by Agilent Technologies, Inc.
This platform not only makes possible the genomic study: wide variation of the number of copies of DNA in high resolution (Barrett, MT, Scheffer, A., Ben-Dor, A., Sampas, N., Lipson, D., Kincaid, R., Tsang, P., Curry, B., Baird, K., Meltzer, PS, et al. (2004). Comparative genomic hybridization using oligonucleotide microarrays and total genomic DNA.
Proceedings of the National Academy of Sciences of the United States of Ameri-. ca 101, 17765-17770.), but also the examination of a specific region of the genome using specifically designed arrangements.
In comparison to traditional aCGH C techniques that rely on cDNA probes or whole BAC probes, 60 mer oligonucleotide probes can thus ensure the specific hybridization and high sensitivity and precision that are necessary. to detect the built chromosomal changes that have been made.
For example, oligos designed to hybridize at - regular intervals along the entire length of the BAC insert would even detect deletions, insertions or other very short rearrangements.
In addition, this platform offers the greatest flexibility for personalized microarray designs.
Genomic DNA from target ES cells and normal human individual genomic DNA will be separately dyed and hybridized to the array.
Arrangement slides will be scanned using Aglient Technologies' DNA microarray scanner.
Reciprocal fluorescence intensities of dye Cy5 and dye Cy3, in every array image, and the ratio values in log will be extracted using the Bluefuse (Bluegnome) software. Spots with inconsistent fluorescence patterns ("confidence" <0.29 or "quality" = 0) will be excluded before all log2 ratio values are normalized. In an experiment, the log2 ratio between -0.29 and +0.29 for the signal emitted by any oligos probe is considered to be unchanged in the number of copies.
The log2 ratio threshold for "Duplication" is generally> 0.29999,
| and for deletion it is <0.29999. Once the first human BAC is inserted into the mouse Ig i locus and confirmed to be in its native, intact Y configuration, the BAC main chain flanked by FRT will be removed by excision with site-specific recombinase for Flp.
If the regular recombination of Flp-catalyzed FRT is not high enough, it is possible to use Flo, an improved version of Flpo recombinase, which in some tests is 3 to 4 times more efficient than the original Flp in ES cells.
After excision of the BAC main chain, ES cells become sensitive to Puromycin (or G418) and resistant to FIAU (by the loss of the TK cassette). The excision events will be characterized in more detail by PCR amplification of the junction fragment, using human genomic DNA primers.
These free ES cells from the BAC main chain flanked. by FRT they will be used for the next round of human BAC insertion for blastocyte injection. : Targeting the genome of an ES cell to produce a transgenic mouse can be done using a protocol - as explained by reference to figures 1–18 attached.
Figure 1 illustrates three basic main chain vectors; an initiation cassette and 2 large vectors inserted, 1 and 2 respectively.
The initiation cassette comprises sequences homologous to the desired insertion site in the mouse genome, these sites flanking a selectable marker and a priming stuffer sequence for PCR-based genotyping and confirmation of correct BAC insertion. Stuffer-initiator provides the basis for genotyping at each step of adding BAC.
This sequence is considered a robust, well-validated sequence model for PCR primer and can be located at the IScel site, ideally at a distance of -1 kb from the inserted BAC.
The large inserted vectors comprise human DNA in - plasmids with selectable markers and a unique restriction site for plasmid linearization in order to assist homologous recombination in the ES cell genome. |
Figure 2 illustrates the insertion of an initiation cassette into the mouse genome by homologous recombination between the mouse J4 and C alpha exons. Puromycin selection allows cells to be identified. ES with cassette insert. pu (Delta) tk is a bifunctional fusion protein between puromycin N-acetyltransferase (Pure) and a truncated version of 'thymidine kinase (DeltaTk) of herpes simplex virus type 1. Murine embryonic stem cells (ES) transfected with pu (Delta) tk become resistant to puromycin and sensitive to 1 - (- 2-deoxy-2-fluor-1-beta-D-arabino-furanosyl) -5-iodouracil (FIAU). Unlike other HSV1 tk transgenes, puDeltatk & is rapidly transmitted via the germline but-. culina. Thus, pu (Deltatk is a convenient positive / negative selectable marker that can be widely used in many ES cell applications.
. Figure 3 illustrates the targeting of the large vector 1 inserted into the mouse ES cell genome. The vector is linearized in the same position as the initiator stuffer sequence that allows a genotyping strategy for gap repair (gap), well known in the state of the art. See Zheng et al NAR 1999, Vol 27, 11, 2354 - 2360. In essence, random insertion of the target vector into the genome will not "repair" the gap, while a homologous recombination event will repair the gap. The juxtaposition of appropriate sequences of PCR primers will allow colonies to be individually screened for a positive fragment by PCR, indicating appropriate insertion. The positive selection using G418 allows the identification of mouse ES cells containing the new selection marker. All critical V, D and J regions can be verified by PCR. Comparative genomic hybridization of arrays can be used to validate the BAC structure. Figure 4 illustrates that the pure-delta-tk cassette and the BAC main chain of the plasmid are deleted using Flpe and selected in —FIAU. Given that Flpe operates inefficiently on mouse ES cells (5% deletion with transient Flpe expression), it is predicted that, in most cases, recombination will occur between the FRT sites flanking | the main chain of the BAC.
Flpo can also be tested to discover the efficiency of the recombination between the two FRT sites that are: a distance of 10 kb. : Since the FRT deletion step is selectable, it is possible to group clones resistant to FIAU and proceed immediately to the next Ú step, parallel to the clonal analysis.
Alternatively, it may be desirable to demonstrate, by short-range PCR, that the human sequences are now adjacent to those of the mouse as shown (primer 1 Hu and primer Mo). At this stage, a 200 kb human locus will have been inserted. . Figure 5 illustrates that a second large inserted vector is directed to the ES cell chromosome.
The human BAC is directed ”to the mouse IgH locus, using the insertion of the same initiation cassette, followed by IScel BAC linearization, directing the BAC to the initiation cassette and gap repair genotyping strategy.
The verification of the insertion of the BAC is carried out as before.
Figure 6 illustrates that the BAC main chain flanked by - FRTY of the large vector 2 inserted and the new marker are deleted via Flpo.
Note that this is not selectable, therefore, clonal analysis will be required at this point.
This will make it possible to confirm the juxtaposition of the human insert 2 with the human 1 and other validation attempts.
At this stage, a - 200Kkb human locus will have been inserted.
Figure 7 illustrates the next large inserted vector targeted to the mouse IgG focus.
The TK pu-delta cassette is then removed, as shown in figure 4. The process can be repeated to incorporate other BAC's.
Figure 8 illustrates the final predicted ES cell construct.
Figures 9 - 18 provide a more detailed level of this process.
Example 2 In a further method of the invention, site-specific recombination can be employed as well.
Site-specific recombination |
(SSR) has been widely used in the past 20 years for the integration of transgenes into defined chromosomal loci.
SSR involves recombination between homologous DNA sequences. . The first generation of chromosomal targeting based on SSR involved recombination between (i) a single target (RT) site of 'loxP or FRT in a plasmid transfected with (il) a RT chromosomal site provided by a prior integration.
A major problem with this approach is that insertion events are rare, since excision is always more efficient than insertion.
A second generation of SSR called RMCE (recombinase-mediated cassette exchange) was introduced - by Schlake and Bode in 1994 (Schlake, T .; J.
Bode (1994). "Use of mutafed FLP-recognition-target- (FRT-) sites for the exchange of expression cassettes” at defined chromosomal loci ". Biochemistry 33: 12746-12751). The method they used was based on the use of two heterospecific and incompatible RTs in the transfected plasmid that can be combined with sites: compatible RTs on the chromosome, resulting in the swapping of a piece of DNA for another - or one cassette exchange.
This approach has been successfully explored in a variety of efficient chromosomal targeting, including integration of BAC inserts over 50 kb (Wallace, HAC, ef al. (2007). "Manipulating the mouse genome to engineering need functional syntenic replacements with human sequence ". Cell 128: 197-209; Prosser, HM et al. (2008)." Mosaic complementation demonstrates a regulatory role for myosin Vila in actin dynamics of Stereocilia ". Mol.
Cell.
Biol. 28: 1702-12). The largest insert size of a BAC is around 300 kb and, therefore, is placed in the upper limit of cassette size for RMCE.
In the present invention, a new technique based on SSR called sequential RMCE (SRMCE) is used, which allows the continuous insertion of BACs inserts in the same locus.
The method comprises the steps of: (1) insertion of DNA forming an initiation cassette (also referred to in this | landing pad specification) in the genome of a cell; (2) insertion of a first DNA fragment at the insertion site, the first DNA fragment comprising a first portion of a human DNA. mano and a first vector portion containing a first selectable marker or generating a selectable marker when inserted; (3) removing part of the vector DNA; (4) insertion of a second DNA fragment into the vector portion of the first DNA fragment, the second DNA fragment containing a second portion of human DNA and a second vector portion, the second vector portion containing a second selectable marker or generating a second selectable marker upon insertion; (5) removing any vector DNA to allow the first and the second human DNA fragment to form a contiguous sequence; and (6) iteration of the steps of inserting a part of the human V (D) J DNA and removing vector DNA as needed to produce a cell: with all or part of the human VDJ or VJ region sufficient to be able to generate a chimeric antibody in conjunction with a constant region of the - host, in which the insertion of at least one DNA fragment uses specific recombination.
In a specific aspect, the approach uses three heterospecific and incompatible loxP sites.
The method consists of the following steps and is illustrated in figures 22 - 26: (1) Targeting a landing pad at the defined locus.
An input vector containing an HPRT minigene flanked by inverted piggyBac (PB) ITRs is directed to the defined region (for example: a region between IGHJ and Eu or IGKJ and Ek or IGLC1 and EA3-1) to serve as a landing pad for targeting BAC.
The HPRT minigene is composed of two synthetic exons and an associated intron.
The 5 'HPRT exon is flanked by two heterospecific and incompatible loxP sites (one wild-type site and the other a mutant site, lox5171) in inverted orientation (figure 22). These two loxP sites provide recombination sites for the insertion of BAC | through RMCE. (2) Insertion of the 1st modified BAC in the target fanding pad.
The 1st BAC has] an extension of DNA to be inserted into the genome flanked by modification. built by engineering.
The 5 'modification (loxP - neo gene - lox2272- PGK promoter - PB 5'LTR) and 3' modification (PB3'LTR - pureATK gene - lox5171) is depicted in figure 23, accompanied by the relative orientations of the sites lox and PB LTRs.
With the transient expression of CRE from an electroporated vector concomitantly, the DNA sequence would be inserted into the locus defined by RMCE.
The cells in which a correct insertion occurred can be selected as follows: (i) Resistance. Puromycin (the pureATK gene acquired a promoter - "PGK" - from the lan- ing pad), (ii) resistance to 6TG (the HPRT minigene was changed) and (iii) resistance to G418 (select any insertion using new PGK arrangement of region 5 '). Any combination of these selection schemes can be used Resistance to G418 and 6TG selects correct events at the '5' end, while resistance to puromycin selects correct events at the 3 'end. - (3) Cure (removal) of the 3 'modification of the 1st insertion.
A properly inserted 1st BAC results in the 3 'end with a pureATK gene flanked by inverted PBLTRs (figure 24) - essentially an appropriate transposon structure.
This transposon can then be removed by the transient expression of the piggyBac transposase (from an electroporated vector). Cells with the correct excision event can be selected for resistance to FIAU - that is, without thymidine kinase activity conferred by the pureATK gene.
This completely removes the 3 'modification leaving no trace of nucleotides. (4) Insertion of a modified 2nd BAC at the 5 'end of the 1st insertion.
The 2nd BAC has an extension of DNA to be inserted into the genome (usually intended to be contiguous with the DNA inserted with the 1st BAC) flanked by modifications built by engineering.
The 5 'modification (loxP - 5' HPRT minigene portion - lox5171 - PGK promoter - PBS'LTR) and 3 'modification (PB3'LTR - pureATK - lox2272) is depicted in figure 25 | accompanied by the relative guidelines of the lox and PB LTRs sites.
With the transient expression of CRE of an electroporated vector concomitantly, the DNA sequence would be inserted into the locus defined by RMCE.
The cells in which a correct insertion occurred can be selected as follows: (i) resistance to HAT (the HPRT minigene is reconstituted by a correct insertion event, that is: the exon structures in 5 'and 3' are joined) and (ii) resistance to puromycin (the pureATK gene acquired a promoter - "PGK" - from the landing pad). (5) Cure (removal) of the 3 'modification of the 2nd insertion.
A properly inserted 2nd BAC results in the 3 'end having a pure ATK gene flanked by inverted PB LTRs (figure 26) - essentially an appropriate transposon structure, exactly analogous to the consequence of a successful 1st 7 BAC insertion.
And therefore, this transposon can also be removed by the transient expression of piggyBac transposase (from an electroporated vector). Cells with the correct excision event can be BR selected for resistance to FIAU - that is, without thymidine kinase activity conferred by the pureATK gene.
This completely removes the modification. 3 'cation leaving no trace of nucleotides. (6) After the 3 'modification of the insertion of the 2nd BAC is cured, the laningpad becomes identical to the original.
The entire process, steps 2 through 5, can be repeated multiple times to build a large insert in the genome.
When complete, there are no residual nucleotides remaining except the desired insert.
With the insertion of an odd number of BAC's in the / loci of lg, the endogenous VDJ or VJ sequences can be inactivated by means of an inversion through chromosomal engineering as follows (see figures 27 - 29): (1) Targeting a flip-over cassette in a 5 'region at a distance of 10 to 40 megabases from the endogenous VDJ or VJ.
The flip-over vector (PB3'LTR - PGK promoter - 5 'portion of the HPRT minigene - loxP - pureATK - CAGGS promoter - PB3'LTR) is depicted in figure 27 together with the relative orientations of the lox and PB LTR sites . |
(2) Transient CRE expression will result in recombination between the loxP site on the flip-over cassette and the loxP site on the 5 'modification. This 5 'modification is as described in Steps 2 and 3 above - essentially the - modification resulting from the insertion of an odd number of BACs, after the 3' modification has been cured.
The loxP sites are inverted in relation to each other and, therefore, the described recombination event results in an inversion as depicted in figure 28. Cells with the correct inversion will be resistant to HAT since the HPRT minigene is reconstituted by a correct inversion. (3) A correct inversion also leaves two transposon structures flan- ing: the flip-over cassette and the 5 'modification. The two can be removed by excision with the transient expression of piggyBAC transposase, 7 ”leaving no residues of any modification (figure 29). Cells with the correct excisions can be selected as follows: (i) resistance to 6TG (the HPRT minigene is deleted) and (ii) resistance to FIAU (the pureATK gene is' deleted). An inversion as described in the lg loci would move the endogenous IGH-VDJ or IGK-VJ region away from the Eu or EK intensifier region, respectively, and lead to inactivation of the endogenous IGH-VDJ or IGK-VJ regions.
The insertion methods of the invention suitably provide one or more of: Selection at the 5 'and 3' ends of the inserted DNA fragment; Efficient cure of the 3 'modification, preferably by excision of DNA mediated by transposase; Inactivation of endogenous IGH or IGK activity through inversion; and Excision of modifications, leaving no remaining traces on the chromosome.
Example 3 The proof of concept of the approach is described in figure 30. In figure 30, a Janding pad, as shown in figure 22, was inserted into the genome of a mouse by homologous recombination, followed by insertion of plasmid R21 in this / anding pad through crepe-mediated site-specific recombination.
The insertion event generated some general insertion events, 360 colonies that were resistant to G418, of which 220 | were inserted in the desired locus, as demonstrated by the rupture of the HRPT minilocus.
The R21 vector mimics the 1st BAC insertion vector in the extremes. 5 'and 3', including all selection elements and target sites for the recombinase. Instead of BAC strings, there is a small "stuffer" sequence. This vector will test all the plots drawn in the invention and will allow to test the results, in the sense that PCR in the stuffer sequence is viable and, therefore, allows both ends of the insert to be easily tested. R21 was electroporated concomitantly with a vector that expressed cre in ES cells harboring the landing pad at the | - - GH locus. Four sets of transformed cells were transfected in parallel and then placed in different selection schemes as shown in figure 30. Selection by G418 (new gene expression) resulted in: greater number of colonies due to there is no requirement for specific integration in the l / anding pad. Any integration of R21 into the 'genome' will give new expression leading to resistance to G418. Selection with pu- romicin resulted in a similar number of colonies for Puro + 6TG or - G418 + 6TG, suggesting that the rigor of puromycin selection results from the pure ATK lacking a promoter in the vector. Puro's expression is only acquired when an integration occurs close to a promoter element - in this design, the most likely is specifically on the landing pad. These conclusions are reinforced by the results of the PCR of the junction which is shown in figure 31. The next step in the invention is to "cure" the 3 'end of the vector —BAC integrated, leaving a continuous transition between the insert and the flanked genome. This cure was demonstrated by expanding an individual clone of the above (R21 inserted in the landing pad) and expressing piggyBac recombines in this clone by transfecting an expressed plasmid. FIAU was used to select colonies in which the 3 'modification was removed by excision - that is, through the loss of the element "PGK-purATK" between the piggyBac terminal repetitions. Fifty such clones resulted from a 10 th cell transfection; of these, 6 were tested | regarding the predicted genomic structure. Successful cure resulted in positive PCR among the primer set marked "3" in figure 32. Of the 6 clones, 4 had correct excisions, | one clone remained in the * original configuration and one other presented a deletion. These data demonstrate iterative insertion of DNA into a laning pad at a defined genomic locus using the approaches described above. Example 4 Example 3 demonstrated that the design of the invention claimed was able to provide the insertion of a test vector in the genome at a defined location, in this case the vector R21 in the mouse IGH locus. The use of an appropriate means of selection and the expression of cre-recombinase 7 resulted in a genomic alteration with the predicted structure. : The same design elements described in this invention were built on the 5 'and 3' ends of a BAC insert. Said insert comprised human sequences from the IGH locus and was approximately 166 kb. This constructed BAC was electroporated along with DNA from: plasmid expressing cre in mouse ES cells harboring the laning pad at the mouse IGH locus. The transfected cell population was cultured in medium containing puromycin to select appropriate insertion events.
Seven resulting clones were isolated and further analyzed. The predicted recombination event and the resulting structure are depicted in figure 33. Based on data obtained from the experiment with —R21 described in Example 3, a rigorous selection for correct clones was predicted when the transfected population was selected on medium containing puromycin. This results from the pure coding region requiring a promoter element and this is preferably supplied by the / anding pad after recombination. In this way, most of the 7 isolated clones were inserted correctly —nogenome in the landing pad as determined by diagnostic PCR. The initiators to diagnose a correct insertion are depicted in the figure
33. Correct junctions are present in the genome if a fragment of 610 | bp is amplified between primers "A" and "X" and a 478 bp fragment is amplified between primers "Y" and "B" (figures 33 and 34). Note that there are amplified fragments between the "A" and "T" primers and the "2" and "B" primers, indicating the presence of a parent genome (that is, only the landingpad). These result from progenitor cells present internally in cell colonies under pure selection that escape selection due to the geometry of a colony.
After the passage of the colony through the medium containing pure, these fragments of the junction of progenitors disappear, indicating that the progenitor cells are removed from the population.
In addition, all clones were shown to be resistant to 6-TG, according to
“Expected me if the HPRT gene is inactivated by the correct insertion event.
These data indicate that the strategy described for inserting large parts of the human GI loci at positions defined in the ca- genome. mundongo will make it possible to build a mouse with a plurality of variable regions of human IG regions in an upward direction.
'refer to the mouse constant regions as described. |

权利要求:
Claims (2)
[1]
1. Method for producing an antibody or light chain or weight of specific antigen for a desired antigen, characterized by the fact that it comprises immunizing a non-human mammal with the desired antigen and recovering the antibody or antibody chain or recovering a cell producing the antibody or light or heavy chain, where the genome of the non-human animal comprises: (a) a plurality of human IgH V regions, one or more human D regions and one or more human J regions upward the constant region of the host non-human mammal; and (b) optionally one or more human kappa light chain V regions of | g and one or more human kappa light chain J regions of lg upwardly to the kappa constant region of the non-human host mammal and / or one or more human lambda light chain V regions delge one or more human lambda light chain J regions of lg upwardly to the lambda constant region of the host non-human mammal; wherein the non-human mammal is capable of producing a repertoire of chimeric antibodies, or chimeric heavy chains and optionally chimeric light chains, having a non-human mammal constant region and a human variable region; and where the insertion of human heavy chain DNA is carried out between the constant region of the non-human mammal and the last, 3 ', J region of the non-human mammal, or where the genome of the non-human animal comprises: (a ) a plurality of human kappa light chain V regions of lg and one or more human J regions of kappa light chain of lg upward to the kappa constant region of the host non-human mammal and / or a plurality of V regions human lambda light chain from Igeuma or other human lambda light chain regions from lg in an upward direction to the lambda constant region of the host non-human mammal; and
It is 2/5: (b) optionally one or more human V regions of IgH, one or more human D regions and one or more human J regions upwardly to the constant region of the host non-human mammal; in which the non-human mammal is capable of producing a repertoire of chimeric antibodies, or chimeric light chains, and optionally heavy chimeric chains, having a non-human mammal constant region and a human variable region, and in which insertion of human kappa or lambda chain DNA is carried out between the non-human mammal constant region and the last, 72, non-human mammal region.
[2]
2. Non-human mammalian antibody-producing cell, characterized by the fact that the genome comprises: (a) a plurality of human V regions of IgH, one or more human D regions and one or more human J regions in an upward direction - tooth to the host non-human mammal constant region and (b) optionally one or more human Ig kappa light chain V regions and one or more human kappa light chain regions of | g upward to the non-mammalian kappa constant region human host and / or one or more human lambda light chain V regions delgeuma or more human lambda Ig light chain regions upward to the lambda constant region of the host non-human mammal; and in which the insertion of human heavy chain DNA is carried out between the constant region of the non-human mammal and the last, 3 ', non-human Jdomamiiferous region, or a non-human antibody producing cell whose genome comprises: ( a) a plurality of human kappa light chain V regions of lg and one or more human J regions of kappa light chain of lg upward to the kappa constant region of the host non-human mammal and / or a plurality of regions Human Ig lambda light chain V and one or more human Ig lambda light chain J regions in
. from the ascendant to the lambda constant region of the host non-human mammal; and: (b) optionally one or more human IgH V regions, one or more human D regions and one or more human J regions upwardly to the constant region of the host non-human mammal; and in which the insertion of human kappa or lambda chain DNA is carried out between the non-human mammal constant region and the last, 3 ', non-human mammal J region.
3. Method for producing an antibody or light chain or weight of specific antigen for a desired antigen, characterized by the fact that it comprises recovering an antibody or antibody chain from a cell as defined in claim 2.
4. Method or cell according to any one of claims 1 to 3, characterized by the fact that the non-human mammalian genome into which DNA is inserted comprises endogenous V (D) J regions that have not been deleted .
5. Method or cell according to any one of claims 1 to 4, characterized by the fact that the non-human mammal is a rodent or the cell is a rodent cell.
6. Method or cell according to any one of claims 1 to 5, characterized by the fact that the non-human mammalian genome comprises DNA inserted from the human variable region of a human heavy chain and human light chain, in that there are: (a) a plurality of human IgH V regions, one or more human D regions and one or more human J regions in an upward direction to the constant region of the host non-human mammal and in which the insertion of the chain DNA human light is upward to a constant region of the non-human mammalian light chain.
7. Method or cell, according to claim 5, characterized by the fact that the mammal is a mouse or the cell is a mouse cell.
'4/5: 8. Method or cell, according to claim 7, characterized by the fact that the insertion of human heavy chain DNA is carried out in a mouse genome between coordinates 114.667.091 and
114,665,190 of mouse chromosome 12 (coordinates refer to NCBI m37, April 2007 ENSEMBL Release 55.37 h for mouse C57BL / 6J strain).
9. Method or cell according to any one of claims 1 to 8, characterized by the fact that the mammalian cell or genome is optionally modified to prevent or reduce the expression of antibodies totally specific to the host species wherein the non-human mammalian genome is modified by reversing all or part of the VDJ region or VJ region of the non-human mammal.
10. Method or cell according to any one of claims 1 to 9, characterized by the fact that the genome of the non-human animal or cell comprises inserted human variable region DNA from at least one human heavy chain and chain light human.
11. Method or cell, according to any one of claims 1 to 10, characterized by the fact that the genome of the non-human animal or cell does not comprise DNA from the constant region of another cell or organism.
12. Method or cell according to any one of claims 1 to 11, characterized in that the genome of the non-human animal or cell comprises a mouse switch sequence.
13. Method or cell according to any of claims 2 to 12, characterized by the fact that the antibody-producing cell is immortalized.
14. Method or cell according to claim 13, characterized by the fact that the cell is an antibody-producing cell immortalized by fusion to a tumor cell to provide an antibody-producing cell and cell line or can be done by direct cellular immortalization.
15. Method for producing a fully humanized antibody or antibody chain, characterized by the fact that it comprises
It is 5/5 S to immunize a non-human mammal as defined in any of claims 1 and 4 to 11, and then replace the non-human mammal constant region of an antibody or chimeric antibody chain specifically reactive with the antigen with a human constant region, optionally engineered by the nucleic acid encoding the antibody or chimeric antibody chain.
16. Use of an antibody or antibody chain produced by the method or cell, as defined in any one of claims 1 to 15, characterized in that it is in medicine or in the production of a pharmaceutical composition.
17. Antibody or chain of antibodies produced by the method, as defined in any one of claims 1 and 3 to 15, characterized by the fact that it is for use in medicine.
18. Pharmaceutical composition, characterized by the fact that it comprises an antibody or anticope chain produced by the method, as defined in any one of claims 1 and 3 to 15, and a pharmaceutically acceptable carrier or other excipient.
19. Chimeric antibody derivative, characterized by the fact that it is a chimeric antibody produced by the method, as defined in any of the claims | e3a15.
20. Invention, in any form of its embodiments or in any applicable category of claim, for example, product or process or use encompassed by the material initially described, revealed or illustrated in the patent application.
Figure 1 Three basic main vector chains Stuffer-initiator 100 bp loxP AP FRT tree, '”EpUo TINA: - Starting cassette Dictation arm- 1 -) BAC-bb à namento == 1kb NR t Targeting arm Tracer meme Plasmid - main chain | aan coco ment FR lScel FRT S lsiNeo fo BACDD Large insert: Vector 1 kb human BAC FRT IScei FRT BAC-bb kb Large insert: Vector 2 human BAC
Figure 2 Input / initiation vector: Step 1 4 Eu Su Cc Bono "MA ox MM - with maesxn— TETE 8 r BAC-bb & Targeting the initiation cassette to the JC Puro intron of the mouse 4 IgP toxp FRT Cc [Ba FEET A - BAC-bb Validation:
1. LR-PCR / Southern gene targeting standard
2. Produce chimeras and reproduce in parallel with the next step.
Figure 3 Addition vector: Step 2 J4 toxP FRT Cc AI s— ET - OP ——— ES * DARK ASI ES BAChbb Huk-primer FRT X Gapped-BAC-bb FRT Large insert: Vector 1 - = CNE 7) Build the Human BAC and direct it and the IgT focus to the FRT Gap-R-primer S Genotyping: Human 1 By linearizing the vector in the same position as inserting the stuffer sequence, it is possible to use a gap repair genotyping strategy, this short-range PCR OS Selection with G41 (1 kb) is highly specific and could be universal 14 joxP FRT FRT FRT Cc —rAr EE - ms Human 1 EO -
Figure 4 Addition vector: Step 2 J4 HulA-primer Cc AD EED rhyme 1 - "p HE toxP FRT FRT & | ê 4 Y Hutá primer Cc Human 1 - o — E— loxP FRT FRT Moprimer
Figure 5 Addition vector: Step 3A 4 C Human 4 —— —— toxP X FRT FRT ram at RATES Large insert: Vector 2 S FRT - Gapped-BACOh FRT Cut and trim the human BAC and direct it to the IgH focus of mouse using Human 2 same linearization site / Sce1 and gap repair genotyping strategy. 4 C Hu2 Hu ——— E— toxP FRT FAT FRT
Figure 6 Addition vector: Step 3B J4 Cc Hu 2 ui —— toxP FRT FRT FRT o À /! 4 Hu2A-primer Cc e) h ETTA -. Hu2 —o— HW - Aa loxP FRT Hu18-primer
Figure 7 Addition vector: Step 4 J4 Cc Hu2 —b— HA loxP X FRT FRT 2— ENeg Large insert: Vector 1 Gapped-BACbD BAC-bb Build the BAC and target it to Ss 6 Human Z mouse IgH locus 3 J4 Cc Humans - ——m = - Human 2 -> - Hmant —E— J4 PA Cc Human 3 —— Human 2 - Human 1 -
Figure 8 Humanized locus of mouse / gH o
R J4 Eu S Cc Human 5 dé d- Human 2> Human 1 so loxP FRT FRT FRT FRT
Figure 9 BAC landing pad inserted in the IgH locus 114,667,091 O as XV o E & DO EE E E S Vo & CS EL CSS] au SE IS SESI vrr1rdicmaeeemmmen CTT 7/7 à loxP BAC landing pad FRT
CE PS »E RS É E W E S o & o & & foxP BAC-bb FRT Validation:
1. LR-POR / Southern gene targeting standard
2. Produce chimeras and test the generation.
Figure 10 1st insertion of BAC - Stage 1
KA AND TS>
CO ZÉ o o ”WWW —BAClandingpad I S EE IS AZ Eee Fra —S o po ioxP FRT 5 Pos SS sa D7-27, 216 AR Gapped-vector FS SL LFLVY SOS +
R IS HHHHHH n EE HIHHE— AH FRT GapR-primer FRT. = do oo DD AIQSSNOSTOS & APS A o
SE FIG FG SIX S FE SFESSFT FS S IgH human BAC 1 = | - selection with G418 180 kb after cutting and EE / SE adjustment
E 07:27, as> p— I S; SS And at Pira — o — o — N--
FRT FRT>> + E CSS S O SE lmss —EHEHHEOA toxP FRT
Figure 11 1st insertion of BAC - Step 2
SE
07.27, J16 = EE I S. HFHRNHHO po)
FAT FRT + ”P QE PO E Apaes HH HH toxP FRT = 2 Expression of FIpO Selection with FIAU S 100% J-segments ZE 100% D-segments 6727 116 FRT costs 6 functional V- segments HH —as — 2— od> LV TESS 8 Esse NES) AHHH loxP FRT 100% of J segments - 100% of D segments - 6 functional V segments
Figure 12 2nd insertion of BAC - Stage 3 and SS D7-27 J16 E) S) EH! | n F> P 2 SY loxP BACIandingpad - FRT E SPSS VT E 3 E - EEE 8> ”Pa Huzprimeç FR XxX Gapped-vector FARTOS TE me eh = = PTE AND human BAC / 2 of 'IgH P“ * GapR-peimer o <P 136 kb after cutting and adjust to: Selection with Pure
Figure 13 2nd insertion of BAC - Stage 4 Vo
FX D727 J16 I S Only the HHHHHo sa H
It is SC Dwarf OP VOS E. = TRE I— A - 655 - AHHH à RM ES Gap-R-primer nm ww x »E) Ed” - FIpO expression Z *. F FIAU selection L—— Es E V Landing pad N
SE 0727 JL6 Eu Su HHHHH— 2-5 o 2
FE Is THESE Landing pad the 7> - s SS & õ Ap) AAA HAHA
Figure 14 BAC landing pad at mouse IgK Ch6 locus: 70,674,735
S SS o ra E O | E:> E Ea AA 11112 = 111] tutto 207000 ridges rem POST 77 R foxP BAClanding pad FRT e: 3 $ E =>: E E3 'foxP BAC-bb FRT Validation:
1. LR-PCR / Southern gene targeting standard
2. Produce chimeras and test the generation.
Figure 15 1st insertion of BAC - Stage 1 o SE o O se E º SD oxP - RT; Y EX MN bags J Lfui-pamedRT Gapped-vector FRT vo vas fi: E. S Gap-R-prime; = | U is à. 1 & range Vv5-2 VI v2-4 VvI-5 Vvr6 v3-7 À BAC 1 human IgK 175 kb after cutting and adjustment Selection with G418. u
É vet 1 So vas dia> gToda Ei É | pn ———— Yeah And Yeah) v15 v16 va-7 Eve so
Figure 16 1st insertion of BAC - Stage 2 and cow * 52 VA À —FRT med E ET E f—— Il + —— n — A5 — s—— vs vs vain E vis IS foxP —FgT> Es ss.
E vs s Expression of FlpO R Selection with FIAU 100% J-segments e. S 6 functional V- Fegments. vs2 vas) "ã N [El & | (E ———— s v vs v37 In v1-s S & vs 100% J segments - 6 functional V segments
Figure 17 2nd insertion of BAC - Stage 3 or 2: 4 3 52 Val to FR E SS: A —li —— s— E vs vis va ES vas É JoxP aC landing pad - FRT à [IgKk human ass and BAC 2; vo 166 kb after cutting and setting = X to
It is Huz-primer FBT Gapped-vector FRT va24 V2-23V1-22 E V3-20 = FERE E E E Er -— EE S> EP vs em & o E Er dm ESA V218 V210 V341 - Vito VLS VIM V34S VIGO VII | Selection with Pure
Figure 18 2nd insertion of BAC - Step 4 va-4 v Vs2 Vaz AS fRT AND SM PHiic—— A vt6 view vLA3 VL12 - V341 V230 view Hoaprimer EM v1.9 A E E.
Re FloO expressio: 1st.
E Is E) FIAU selection a VLIAV315 VIIJ6 VII7 / 2-18V2-19V3-20 EMEA go ESE loxP BAClanding pad Vea VED3 and Va-5 v24 V3 V52 vaz 145 E É P —— HAA HAHA É - + 1 + vis v37 NE VE) V2: 10 V311 Vil2 VB In. ADA É R 8 F healthy E ES A— E HH o | EA loxP BAC landing pad V2-24 V2-23V1-22 V6-21 V3-20V1-19V2-18 VI-17 / - VL-16. V3-15V2-14 100% of J segments; 14 functional V segments
Figure 19 Rapid ES cell tests with humanized IgH and IgK / oci RAG - / - TryBrd ENS ANSA ESSA RIAA 7 CREME cs - E gnho / So sh PER gkhy / Pa leKkhu / - 200%) 1045% We "ê E sa TE, AR, STERN ESSE AEE SA, 100% B cells 100% B cells originated 20 80% derived from primary cells of injected injected ES ES ES cells
Figure 20 Antibody generation in chimeric mice with humanized lgH and Igk RAG - / - Cc TryBrd loci
SNCT EFE STE ME lignur ão 2 read hu / - Po CAE ok hu / CAE lgK hu / - E e and EX if SO and ROAD RES SO SEDIA YEAR Nm IF Ear AT BAKED SEE TRA ERAS TANDO B
S 10-15% NA 70-80% 100% e; | Exposure to ER antigen ER IS PA, CE TO ES FP: "> MEREÇO IS" Es S "ss Is 100% of B cells originating- 100% of B cells originating 20- 80% of injected ES cells from injected ES cells derived from
ES
Figure 21 Insertion site ACI IA BET OS): Mouse | RR I d s- pa
THIS MABB6ST1
NM Nx Wa Ss HCHrI4: 106,365,585 HEhri4: 105400.081 ausa Human "Mouse Já je VA TA Humas“ É NS t Human VD. L 4
It is | F Including 400 bp human sec after Hu J6 Insertion site Incorrio siphon MCRIZ 114 867 06) MONI2 17266709: (duplication of 1 mouse bp'
Figure 22 Targeting the / andiíng pad Ma «F468 02! EIHOSEEIQATHETVWDTSNNEENEEEZAS and ——— p— RA to A LO - FAITH A. [The LoxP Lox5171 ASS CDA ESET Color - NE. O
PP] HAT toxP Lox5i71
Figure 23 Insertion of the 1st BAC tLoxP LtoxS171
NS TETE To cosoaçe: N and LoxP Loo LoxSi71 mm Sm s BAC1 R l G418, 61G LloxP LoxZ272 Pure toxs171 BAC1
Figure 24 Healing the modification in 3 LloxP Lox2272 tox5171 2
R] PB expression
FIAU toxP Lox2272 BAC 1
Figure 25 Insertion of the 2nd BAC loxP tox2272 BACL o LoxP toxs171 tox2272 Nm to BAC2 gg] 1 HAT, Pure LoxP tox5171 tox2272 Com> BAC1 BAC2
Figure 26 Removing the 3 'LtoxP modification Lox5171 Lox2272 weigh A distaff. ME EE so s] 1 PB S expression
FIAU LoxP Lox5171 os EEE AEE, BAC2 —— BACL ——
Figure 27 Directing the vector “Flip-Over”> 10Mb LoxP Lox2272
BAC - ros EEE DEE:> LF At, FÊ To FP toxP Ts,
E NE <a) mem s
W] 1 Pure D LoxP LoxP Lox2272
Figure 28 LoxP toxP inversion Lox2272 | 1 Expression of CRE õ 2
R R to HAT , Pure loxP Lox2272
Figure 29 Removing all LoxP modifications
NM
FAITH
SR toxP Lox2272 Cos os QUEEN ro> year -] 1 Expression of PB 6TG, FIAU
Figure 30 Sequential RMCE - Integration on / landing pad, LoxP tons171, OD
DEI LÓ rs Landing pad of RMCE O Ne on chromosome Pr Stuffer / BAC AS LtoxP Lox2272 tox5171 -. : the EI CNE & O Fasta R91 vector> R21 transfected with Cre M expression cassette —— u —— »—— Ú Selection: Puro Puro + 6TG G418 G418 + 6TG Node colonies: - 239 220 360 198
Figure 31 Confirmation of successful insertion on landing pad Colonies: Resistant to 6-TG and Pure *> s LEARN eg: Initiator contour - (DI: 2900 24 correct Initiator set 5 '' "- = (AD) 23de24cometes Summary: THESE AE CR ERDAEAENO EEE AA RREO Ez name DE nd Te scam O ae o | am o
Figure 32 PCR confirmation of 3 'Stuffer / BAC toxP cure Lox2272 LoXx5171 Cos E-ÓEE | os oo AEo> o> -, & o & 102272 Stuffer / BAC PB expression toxP lox / FIAU & 3 * FIAU resistant colonies 1 23456 (Total of the 50 of 10th brains) = GRRSEATGDDAO
E - CD% GM - Curabempered - o Original configuration
Figure 33 Insertion of BAC nº 1 - Diagnosis by PCR ua ras
D N EE ”o BAC1 Ss +" EN. E qe In EE BAC1 A <> X = 610bp | Insertion Y <> B = 478bp | correct ASs> 1 = 390bp |: Configuration 2 <> B = 659bp | original
Figure 34 Insertion of Bac # 1 - Diagnosis by POR * Wo 1 2 3 4 5 6 7 1 7 1 bo i 4 t: | :: Í = | IADE 3 RR ES UI | IN THIS A <> X = 610bp s10 = Esto "..: is ER | v 2-478b0 SA DEN o 1 TO ASR cs FS AND EDNA AN EN CAN = |: TT Fi É L | rodeos AE - As <> 1 = 390bp | 659 = EUTANE: ESA bos la São - bmiA | Psi AR | 2 <> B8 = 659bp | Jet oa o O * Clones nº 2, 5 and 6 have BAC nº 1 inserted Clones nº 1, 3, 4 and 7 probably have BAC # 1 inserted, but the samples are mixed with progenitor cell lines.
Ê SUMMARY Patent of Invention: "METHODS FOR PRODUCTION OF ANTIBODY OR
IT IS LIGHT OR HEAVY CHAIN OF ANTIBODY SPECIFIC TO A DESIRED ANTIGEN, FOR THE PRODUCTION OF TOTALLY HUMANIZED ANTIBODY OR ANTIBODY CHAIN OR ANTIBODY CHAIN AND ITS USE, PHARMACEUTICAL COMPOSITION AND DERIVATIVE OF ANTIBODY. methods for the generation of human chimeric antibodies - non-human and chimeric chains of antibodies, antibodies and chains of antibodies thus produced, and their derivatives, including fully humanized antibodies; compositions comprising said antibodies, chains and derivatives antibodies, as well as cells, non-human mammals and vectors, suitable for use in said methods.

类似技术:

---

公开号 | 公开日 | 专利标题

---

AU2018206729B2|2020-10-08|Animal models and therapeutic molecules

---

JP6876853B2|2021-05-26|Animal models and therapeutic molecules

同族专利:

---

公开号 | 公开日

---

EP2421357B1|2013-01-23|

---

EP3622813B1|2021-02-17|

---

EP2604111A3|2013-12-18|

---

EP2604110B1|2016-11-30|

---

EP2517556A3|2013-07-17|

---

NO2792236T3|2018-04-14|

---

PT2564695E|2015-06-03|

---

AU2018206729B2|2020-10-08|

---

EP2792236A2|2014-10-22|

---

EP2792236A3|2014-11-12|

---

EP2604110A3|2013-08-14|

---

EP2517556B1|2015-11-18|

---

EP3028564A1|2016-06-08|

---

AU2018206729A1|2018-08-02|

---

WO2011004192A1|2011-01-13|

---

DK2798950T3|2017-05-22|

---

EP2517557A3|2013-07-24|

---

EP2564695A1|2013-03-06|

---

JP2012532598A|2012-12-20|

---

JP5944312B2|2016-07-05|

---

DK2421357T3|2013-04-15|

---

PL3241435T3|2021-12-13|

---

SG177380A1|2012-02-28|

---

PL2564695T3|2015-10-30|

---

EP3028565A1|2016-06-08|

---

AU2016244326A1|2016-11-03|

---

EP3028565B1|2017-09-27|

---

DK2564695T3|2015-05-26|

---

CN102638971A|2012-08-15|

---

EP2517557A2|2012-10-31|

---

CA2767436A1|2011-01-13|

---

EP3871497A1|2021-09-01|

---

EP2604111A2|2013-06-19|

---

NZ597481A|2013-10-25|

---

US20150334998A1|2015-11-26|

---

EP2517557B1|2016-04-13|

---

AU2021200079A1|2021-03-18|

---

EP2792236B1|2017-11-15|

---

SI3241435T1|2021-11-30|

---

KR20130042461A|2013-04-26|

---

AU2010269978B2|2016-11-03|

---

DK2604110T3|2017-02-13|

---

EP2798950B1|2017-04-19|

---

PT2421357E|2013-04-18|

---

CN105340834B|2018-11-06|

---

ES2884309T3|2021-12-10|

---

US20160150768A1|2016-06-02|

---

SG2014010995A|2014-05-29|

---

DK3241435T3|2021-08-23|

---

EP3241435B1|2021-05-26|

---

PT3241435T|2021-08-26|

---

AU2010269978A1|2012-02-02|

---

CN102638971B|2015-10-07|

---

EP2421357A1|2012-02-29|

---

DK3622813T3|2021-05-03|

---

DK2792236T3|2018-01-02|

---

EP2604110A2|2013-06-19|

---

SI2421357T1|2013-06-28|

---

EP3028564B1|2017-09-27|

---

LT3241435T|2021-10-25|

---

ES2537239T3|2015-06-03|

---

HUE055817T2|2021-12-28|

---

EP3622815A1|2020-03-18|

---

EP3241435A1|2017-11-08|

---

EP3622814A1|2020-03-18|

---

EP3622813A1|2020-03-18|

---

PT2517556E|2016-01-20|

---

ES2403087T3|2013-05-14|

---

PL2517556T3|2016-03-31|

---

KR101875233B1|2018-07-05|

---

CN105340834A|2016-02-24|

---

DK3028564T3|2017-11-13|

---

EP2564695B1|2015-04-15|

---

EP3871498A1|2021-09-01|

---

DK2517557T3|2016-05-30|

---

DK3028565T3|2017-11-13|

---

EP3888457A1|2021-10-06|

---

PL2421357T3|2013-07-31|

---

EP2798950A1|2014-11-05|

---

ES2557737T3|2016-01-28|

---

DK2517556T3|2016-01-11|

---

EP2517556A2|2012-10-31|

---

AU2016244326B2|2018-04-26|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

AU633698B2|1990-01-12|1993-02-04|Amgen Fremont Inc.|Generation of xenogeneic antibodies|

---

US7041871B1|1995-10-10|2006-05-09|Genpharm International, Inc.|Transgenic non-human animals capable of producing heterologous antibodies|

---

US6255458B1|1990-08-29|2001-07-03|Genpharm International|High affinity human antibodies and human antibodies against digoxin|

---

AU2515992A|1991-08-20|1993-03-16|Genpharm International, Inc.|Gene targeting in animal cells using isogenic dna constructs|

---

US5859307A|1992-02-04|1999-01-12|Massachusetts Institute Of Technology|Mutant RAG-1 deficient animals having no mature B and T lymphocytes|

---

ES2308327T3|1997-11-18|2008-12-01|Pioneer Hi-Bred International, Inc.|COMPOSITIONS AND METHODS FOR GENETIC MODIFICATION OF PLANTS.|

---

ES2201567T3|1997-12-05|2004-03-16|Europaisches Laboratorium Fur Molekularbiologie |NEW DNA CLONING METHOD BASED ON THE RECE-RECT RECOMBINATION SYSTEM OF E. COLI.|

---

EP0939120A1|1998-02-27|1999-09-01|Gesellschaft für biotechnologische Forschung mbH |Method for marker-free repetitive DNA expression cassette exchange in the genome of cells or parts of cells|

---

US6355412B1|1999-07-09|2002-03-12|The European Molecular Biology Laboratory|Methods and compositions for directed cloning and subcloning using homologous recombination|

---

CA2307503A1|2000-05-02|2001-11-02|Carlos F. Barbas Iii|Peptides for use as a vaccine or treatment for hiv infection|

---

CN1455817A|2000-07-21|2003-11-12|美利坚合众国|Methods for replacement, translocation and stacking of DNA in eukaryotic genomes|

---

US6596541B2|2000-10-31|2003-07-22|Regeneron Pharmaceuticals, Inc.|Methods of modifying eukaryotic cells|

---

JP2005505236A|2000-12-19|2005-02-24|アルトーバイオサイエンスコーポレイション|Transgenic animals including humanized immune system|

---

FR2827302B1|2001-07-13|2003-10-10|Genoway|TRANSGENIC CELL AND ANIMAL MODELING HUMAN ANTIGENIC PRESENTATION AND USES THEREOF|

---

DK1461442T3|2001-11-30|2017-12-04|Amgen Fremont Inc|Transgenic animals with human Ig lambda light chain genes|

---

US7700356B2|2002-11-08|2010-04-20|The United States Of America As Represented By The Secretary Of Agriculture|System for gene targeting and producing stable genomic transgene insertions|

---

DE10251918A1|2002-11-08|2004-05-19|Horn, Carsten, Dipl.-Biochem. Dr.|Inheritable integration of DNA into germ-line invertebrate cells, useful for large-scale production of transgenic insects, includes post-transformational removal of mobilizable elements to increase stability|

---

CN1326878C|2003-04-29|2007-07-18|中国抗体制药有限公司|Anti human non-Hodgkin's lymphoma chimeric antibody and its derivative and application|

---

WO2005001087A2|2003-06-11|2005-01-06|Regeneron Pharmaceuticals, Inc.|Methods of modifying genes in eukaryotic cells|

---

GB2403475B|2003-07-01|2008-02-06|Oxitec Ltd|Stable integrands|

---

US7663017B2|2003-07-30|2010-02-16|Institut Pasteur|Transgenic mice having a human major histocompatability complex phenotype, experimental uses and applications|

---

US7625549B2|2004-03-19|2009-12-01|Amgen Fremont Inc.|Determining the risk of human anti-human antibodies in transgenic mice|

---

CA2827654C|2004-10-19|2019-04-02|Regeneron Pharmaceuticals, Inc.|Method for generating an animal homozygous for a genetic modification|

---

EP1896578A4|2005-05-14|2008-11-05|Univ Fudan|Piggybac as a tool for genetic manipulation and analysis in vertebrates|

---

US7462759B2|2006-02-03|2008-12-09|Pioneer Hi-Bred International, Inc.|Brittle stalk 2 gene family and related methods and uses|

---

US7910798B2|2006-03-31|2011-03-22|Medarex, Inc.|Transgenic animals expressing chimeric antibodies for use in preparing human antibodies|

---

MY147468A|2006-06-02|2012-12-14|Regeneron Pharma|High affinity antibodies to human il-6 receptor|

---

US7709257B2|2006-06-27|2010-05-04|Vax Design Corp.|Models for vaccine assessment|

---

CA2664343C|2006-10-02|2016-04-26|Regeneron Pharmaceuticals, Inc.|High affinity human antibodies to human il-4 receptor|

---

US7732195B2|2006-11-01|2010-06-08|Facet Biotech Corporation|Tethered vectors for cell surface immunoglobulin display|

---

RU2448979C2|2006-12-14|2012-04-27|Ридженерон Фармасьютикалз, Инк.|Human antibodies to delta-like human ligand-4|

---

GB0700194D0|2007-01-05|2007-02-14|Univ Edinburgh|Humanisation of animals|

---

WO2009013620A2|2007-06-11|2009-01-29|Erasmus University Medical Center Rotterdam|Homologous recombination|

---

PL2178916T3|2007-07-31|2015-08-31|Regeneron Pharma|Human antibodies to human cd20 and method of using thereof|

---

WO2009023540A1|2007-08-10|2009-02-19|Regeneron Pharmaceuticals, Inc.|High affinity human antibodies to human nerve growth factor|

---

US20110119779A1|2007-12-10|2011-05-19|Aliva Biopharmaceuticals, Inc.|Methods for sequential replacement of targeted region by homologous recombination|

---

US8227577B2|2007-12-21|2012-07-24|Hoffman-La Roche Inc.|Bivalent, bispecific antibodies|

---

US20110123527A1|2008-05-23|2011-05-26|Hiroaki Shizuya|Method of generating single vl domain antibodies in transgenic animals|

---

EP3456190B1|2008-06-27|2021-11-24|Merus N.V.|Antibody producing transgenic murine animal|

---

CA3038954A1|2008-09-30|2010-04-08|Ablexis, Llc|Non-human mammals for the production of chimeric antibodies|

---

SG172176A1|2008-12-18|2011-07-28|Univ Erasmus Medical Ct|Non-human transgenic animals expressing humanised antibodies and use therof|

---

US20120204278A1|2009-07-08|2012-08-09|Kymab Limited|Animal models and therapeutic molecules|

---

WO2011158009A1|2010-06-17|2011-12-22|Kymab Limited|Animal models and therapeutic molecules|

---

GB0911846D0|2009-07-08|2009-08-19|Genome Res Ltd|Animal models and therapeutic molecules|

---

EP2517557B1|2009-07-08|2016-04-13|Kymab Limited|Animal models and therapeutic molecules|

---

GB0913102D0|2009-07-28|2009-09-02|Genome Res Ltd|Animal models and therapeutic molesules|

---

KR102283195B1|2010-02-08|2021-07-29|리제너론 파마슈티칼스 인코포레이티드|Common light chain mouse|

---

MY165287A|2010-06-22|2018-03-21|Regeneron Pharma|Mice expressing a light chain with human lambda variable and mouse constant regions|US6596541B2|2000-10-31|2003-07-22|Regeneron Pharmaceuticals, Inc.|Methods of modifying eukaryotic cells|

---

CA3038954A1|2008-09-30|2010-04-08|Ablexis, Llc|Non-human mammals for the production of chimeric antibodies|

---

EP2517557B1|2009-07-08|2016-04-13|Kymab Limited|Animal models and therapeutic molecules|

---

US20120204278A1|2009-07-08|2012-08-09|Kymab Limited|Animal models and therapeutic molecules|

---

WO2011158009A1|2010-06-17|2011-12-22|Kymab Limited|Animal models and therapeutic molecules|

---

US20130045492A1|2010-02-08|2013-02-21|Regeneron Pharmaceuticals, Inc.|Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain|

---

US9796788B2|2010-02-08|2017-10-24|Regeneron Pharmaceuticals, Inc.|Mice expressing a limited immunoglobulin light chain repertoire|

---

AU2013204140B2|2012-03-06|2016-01-28|Regeneron Pharmaceuticals, Inc.|Common light chain mouse|

---

KR102283195B1|2010-02-08|2021-07-29|리제너론 파마슈티칼스 인코포레이티드|Common light chain mouse|

---

CA3006800A1|2010-03-31|2011-10-06|Ablexis, Llc|Genetic engineering of non-human animals for the production of chimeric antibodies|

---

MY165287A|2010-06-22|2018-03-21|Regeneron Pharma|Mice expressing a light chain with human lambda variable and mouse constant regions|

---

US10662256B2|2010-07-26|2020-05-26|Trianni, Inc.|Transgenic mammals and methods of use thereof|

---

US10793829B2|2010-07-26|2020-10-06|Trianni, Inc.|Transgenic mammals and methods of use thereof|

---

JP6482757B2|2010-07-26|2019-03-13|トリアンニ インコーポレイテッドＴｒｉａｎｎｉ，Ｉｎｃ．|Transgenic animals and methods of use|

---

WO2012018764A1|2010-08-02|2012-02-09|Regeneron Pharmaceuticals, Inc.|Mice that make binding proteins comprising vl domains|

---

ES2748832T3|2011-02-25|2020-03-18|Regeneron Pharma|ADAM6 mice|

---

KR20190107761A|2011-03-09|2019-09-20|셀 시그널링 테크놀러지, 인크.|Methods and reagents for creating monoclonal antibodies|

---

HUE047278T2|2011-08-05|2020-04-28|Regeneron Pharma|Humanized universal light chain mice|

---

WO2013041845A2|2011-09-19|2013-03-28|Kymab Limited|Animals, repertoires & methods|

---

EP3128009B1|2011-09-19|2020-07-29|Kymab Limited|Antibodies, variable domains & chains tailored for human use|

---

GB2495083A|2011-09-26|2013-04-03|Kymab Ltd|Human VpreB and chimaeric surrogate light chains in transgenic non-human vertebrates|

---

EP2761008A1|2011-09-26|2014-08-06|Kymab Limited|Chimaeric surrogate light chainscomprising human vpreb|

---

PL2627773T3|2011-10-17|2017-11-30|Regeneron Pharmaceuticals, Inc.|Restricted immunoglobulin heavy chain mice|

---

MY164836A|2011-10-28|2018-01-30|Regeneron Pharma|Genetically modified major histocompatibility complex mice|

---

US9591835B2|2011-10-28|2017-03-14|Regeneron Pharmaceuticals, Inc.|Genetically modified major histocompatibility complex animals|

---

PL3424947T3|2011-10-28|2021-06-14|Regeneron Pharmaceuticals, Inc.|Genetically modified t cell receptor mice|

---

US9043996B2|2011-10-28|2015-06-02|Regeneron Pharmaceuticals, Inc.|Genetically modified major histocompatibility complex animals|

---

GB2496375A|2011-10-28|2013-05-15|Kymab Ltd|A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof|

---

RU2660564C2|2011-10-28|2018-07-06|Регенерон Фармасьютикалз, Инк.|Genetically modified mice expressing chimeric major histocompatibility complex molecules|

---

MX356429B|2011-12-20|2018-05-29|Regeneron Pharma|Humanized light chain mice.|

---

GB201122047D0|2011-12-21|2012-02-01|Kymab Ltd|Transgenic animals|

---

DK3597038T3|2012-02-01|2021-06-28|Regeneron Pharma|Humanized rodents expressing heavy chains containing VL domains|

---

ES2849349T3|2012-03-16|2021-08-17|Regeneron Pharma|Histidine Engineered Light Chain Antibodies and Genetically Modified Rodents for Generation|

---

US20140013456A1|2012-03-16|2014-01-09|Regeneron Pharmaceuticals, Inc.|Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same|

---

CA2865644A1|2012-03-16|2013-09-19|Regeneron Pharmaceuticals, Inc.|Mice that produce antigen-binding proteins with ph-dependent binding characteristics|

---

EP2825037B1|2012-03-16|2019-05-01|Regeneron Pharmaceuticals, Inc.|Rodents expressing ph-sensitive immunoglobulin sequences|

---

US10251377B2|2012-03-28|2019-04-09|Kymab Limited|Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies|

---

US9253965B2|2012-03-28|2016-02-09|Kymab Limited|Animal models and therapeutic molecules|

---

US9445581B2|2012-03-28|2016-09-20|Kymab Limited|Animal models and therapeutic molecules|

---

EP2831245A1|2012-03-28|2015-02-04|Kymab Limited|Transgenic non-human vertebrate for the expression of class - switched, fully human, antibodies|

---

GB2501753A|2012-05-04|2013-11-06|Kymab Ltd|Human antibodies|

---

GB2502127A|2012-05-17|2013-11-20|Kymab Ltd|Multivalent antibodies and in vivo methods for their production|

---

KR102266274B1|2012-06-12|2021-06-17|리제너론 파마슈티칼스 인코포레이티드|Humanized non-human animals with restricted immunoglobulin heavy chain loci|

---

SI2931030T1|2012-12-14|2020-10-30|Open Monoclonal Technology, Inc.|Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same|

---

RU2017114166A|2013-02-20|2019-01-29|Регенерон Фармасьютикалс, Инк.|NON-HUMAN ANIMALS WITH MODIFIED SEQUENCES OF HEAVY IMMUNOGLOBULIN CHAINS|

---

ES2736052T3|2013-02-20|2019-12-23|Regeneron Pharma|Mice expressing humanized T-cell co-receptors|

---

US20150342163A1|2013-02-22|2015-12-03|Regeneron Pharmaceuticals, Inc.|Genetically modified major histocompatibility complex mice|

---

KR102211267B1|2013-02-22|2021-02-04|리제너론 파아마슈티컬스, 인크.|Mice expressing humanized major histocompatibility complex|

---

US9788534B2|2013-03-18|2017-10-17|Kymab Limited|Animal models and therapeutic molecules|

---

US9783618B2|2013-05-01|2017-10-10|Kymab Limited|Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics|

---

US9783593B2|2013-05-02|2017-10-10|Kymab Limited|Antibodies, variable domains and chains tailored for human use|

---

AU2014330922A1|2013-10-01|2016-03-03|Kymab Limited|Animal models and therapeutic molecules|

---

DE112016001013T5|2015-03-03|2017-12-21|Kymab Limited|ANTIBODIES, USES AND METHODS|

---

GB201403775D0|2014-03-04|2014-04-16|Kymab Ltd|Antibodies, uses & methods|

---

RU2016141307A3|2014-03-21|2018-10-24|

---

KR20160131118A|2014-03-21|2016-11-15|리제너론 파마슈티칼스 인코포레이티드|Vl antigen binding proteins exhibiting distinct binding characteristics|

---

SG10201913804WA|2014-06-06|2020-03-30|Regeneron Pharma|Methods and compositions for modifying a targeted locus|

---

JP2017521079A|2014-07-14|2017-08-03|ワシントン ステイト ユニバーシティ|NANOS knockout to excise germline cells|

---

GB201418713D0|2014-10-21|2014-12-03|Kymab Ltd|Bindings Proteins|

---

US11111314B2|2015-03-19|2021-09-07|Regeneron Pharmaceuticals, Inc.|Non-human animals that select for light chain variable regions that bind antigen|

---

CN113349159A|2015-04-06|2021-09-07|瑞泽恩制药公司|Humanized T cell-mediated immune response in non-human animals|

---

EP3384030A4|2015-12-03|2019-07-03|Trianni, Inc.|Enhanced immunoglobulin diversity|

---

JP6929877B2|2016-02-04|2021-09-01|トリアニ・インコーポレイテッドＴｒｉａｎｎｉ， Ｉｎｃ．|Enhancement of immunoglobulin production|

---

WO2017163049A1|2016-03-21|2017-09-28|Kymab Limited|Anti-malarial antibodies that bind circumsporozoite protein|

---

US11066464B2|2016-03-21|2021-07-20|Kymab Limited|Anti-malarial antibodies that bind circumsporozoite protein|

---

CN113907043A|2016-06-03|2022-01-11|瑞泽恩制药公司|Non-human animals expressing exogenous terminal deoxynucleotidyl transferase|

---

EP3471754A1|2016-06-20|2019-04-24|Kymab Limited|Anti-pd-l1 antibodies|

---

US9567399B1|2016-06-20|2017-02-14|Kymab Limited|Antibodies and immunocytokines|

---

WO2018029474A2|2016-08-09|2018-02-15|Kymab Limited|Anti-icos antibodies|

---

WO2018065552A1|2016-10-06|2018-04-12|Innate Pharma|Anti-cd39 antibodies|

---

WO2018083248A1|2016-11-03|2018-05-11|Kymab Limited|Antibodies, combinations comprising antibodies, biomarkers, uses & methods|

---

RU2757665C2|2016-11-04|2021-10-20|Регенерон Фармасьютикалс, Инк.|Animals other than humans with constructed locus of light lambda chain of immunoglobulin|

---

WO2018138297A1|2017-01-27|2018-08-02|Kymab Limited|Anti-opg antibodies|

---

GB2561352A|2017-04-10|2018-10-17|Genome Res Ltd|Animal models and therapeutic molecules|

---

GB201709970D0|2017-06-22|2017-08-09|Kymab Ltd|Bispecific antigen-binding molecules|

---

RU2020118699A|2017-12-05|2022-01-10|Регенерон Фармасьютикалз, Инк.|NON-HUMAN ANIMALS HAVING AN ENGINEERED LAMBDA IMMUNOGLOBULIN LIGHT CHAIN AND THEIR USE|

---

GB201721338D0|2017-12-19|2018-01-31|Kymab Ltd|Anti-icos Antibodies|

---

CA3093995A1|2018-03-24|2019-10-03|Regeneron Pharmaceuticals, Inc.|Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof|

---

CN108486126A|2018-03-27|2018-09-04|重庆金迈博生物科技有限公司|A kind of nucleic acid molecules and its application in humanized antibody|

---

CA3103646A1|2018-06-14|2019-12-19|Regeneron Pharmaceuticals, Inc.|Non-human animals capable of engineered dh-dh rearrangement and uses thereof|

---

GB2576914A|2018-09-06|2020-03-11|Kymab Ltd|Antigen-binding molecules comprising unpaired variable domains produced in mammals|

---

GB201815629D0|2018-09-25|2018-11-07|Kymab Ltd|Antagonists|

---

GB201820687D0|2018-12-19|2019-01-30|Kymab Ltd|Antagonists|

---

WO2021105389A1|2019-11-29|2021-06-03|Kymab Limited|Treatment for physiological iron overload|

---

WO2021113297A1|2019-12-02|2021-06-10|Regeneron Pharmaceuticals, Inc.|Peptide-mhc ii protein constructs and uses thereof|

法律状态:
2020-08-18| B06U| Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]|

---

2020-12-15| B07D| Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]|Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |

---

2021-04-27| B07E| Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]|

---

2021-10-13| B07A| Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]|

---

2021-11-03| B350| Update of information on the portal [chapter 15.35 patent gazette]|

优先权:

---

申请号 | 申请日 | 专利标题

---

US22396009P| true| 2009-07-08|2009-07-08|

---

US61/223,960|2009-07-08|

---

GB0911846.4|2009-07-08|

---

GBGB0911846.4A|GB0911846D0|2009-07-08|2009-07-08|Animal models and therapeutic molecules|

---

GB0913102A|GB0913102D0|2009-07-28|2009-07-28|Animal models and therapeutic molesules|

---

GB0913102.0|2009-07-28|

---

US35566610P| true| 2010-06-17|2010-06-17|

---

US61/355,666|2010-06-17|

---

PCT/GB2010/051122|WO2011004192A1|2009-07-08|2010-07-07|Animal models and therapeutic molecules|

---